Document:

<PAGE>

                                                                    Exhibit 10.8

                  ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT

     ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT dated as of October 7, 1999
(the "Agreement") by and between IMARX, LLC, an Arizona limited liability
company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an Arizona corporation
("Seller"). Capitalized terms used but not otherwise defined herein have the
meanings assigned to them in the Technology Agreements (as defined below).

                                    RECITALS

     A. Seller is engaged in the research and development of pharmaceutical
products. Among other assets, Seller owns certain patents and patent
applications in the field of ultrasound diagnostic imaging. Seller has
previously assigned and/or licensed certain of its patents and patent
applications to DuPont Pharmaceuticals Company ("DuPont") pursuant to the
Assignment and License Agreement dated October 23, 1995 and the License and
Marketing Agreement dated October 23, 1995, and amendments thereto (hereinafter
collectively referred to as the "Technology Agreements").

     B. DuPont has made an offer to acquire the stock of Seller, provided that
Seller divests itself of certain assets and liabilities. The parties anticipate
that Seller will be merged into a subsidiary of DuPont (the "Merger") pursuant
to an Agreement and Plan of Merger (the "Acquisition Agreement").

     C. Purchaser will assume all liabilities of Seller other than those
liabilities specifically retained by Seller and accepted by DuPont in the
Acquisition Agreement (the "Assumed Liabilities"). Purchaser wishes to acquire
certain assets of Seller (including the "Physical Assets and Receivables" and
the "Category III Assets") identified on Exhibit A. Seller wishes to license the
Category III Assets back from Purchaser for use within the field of contrast
enhancement of diagnostic ultrasound imaging, but specifically excluding
targeted and tissue specific diagnostic ultrasound products. This field of use
is referred to herein as "CEDUI."

     D. Purchaser wishes to license from Seller certain assets to be acquired by
DuPont in connection with the Acquisition Agreement (the "Category II Assets")
identified on Exhibit B for use outside of CEDUI.

     E. Seller wishes to secure from Purchaser a right of first negotiation with
respect to new products developed by Purchaser in the fields of thrombus imaging
and sonothrombolysis.

     F. The parties wish to agree on certain procedures and responsibilities for
addressing certain claims of infringement that may arise from Seller's practice
of its technology.

     G. The execution and delivery of this Agreement by Purchaser is a condition
to the obligations of Seller to consummate the transactions contemplated by the
Acquisition Agreement.

<PAGE>

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Acquisition Agreement, Purchaser and
Seller agree as follows:

1.   Assignment of Assets.

     a.   Seller hereby grants, conveys, sells, transfers and assigns to
          Purchaser, free and clear of all debts, obligations, liens and
          encumbrances (other than the Assumed Liabilities, as that term is
          defined below) all of the assets described on Exhibit A hereto;
          provided, however, that the Category III Assets shall not include any
          Assets to be acquired by DuPont in the Merger.

     b.   Seller hereby assigns to Purchaser its rights under the Assigned
          Patents, as that term is defined in the Technology Agreements, which
          rights are fully set forth and described in Section 3 of the
          Assignment and License Agreement dated October 23, 1995. Purchaser's
          license rights granted therein will survive any termination,
          cancellation, or modification of the Assignment and License Agreement
          by Seller.

2.   Assignment of Name. Effective as of the date of Closing pursuant to the
     Acquisition Agreement, Seller hereby assigns the name "ImaRx
     Pharmaceuticals" along with any variations thereof to Purchaser along with
     the goodwill associated with the Category III Assets. Seller will execute
     any additional documents necessary to transfer the name to Purchaser.

3.   Assumption of Liabilities. Seller hereby assigns to Purchaser, and
     Purchaser hereby assumes and agrees to pay, perform and discharge, and to
     indemnify Seller against and hold it harmless from all of the liabilities
     and obligations of Seller accrued or arising before the Closing (as that
     term is described in the Acquisition Agreement), including without
     limitation those Liabilities set forth on Exhibit D hereto (the "Assumed
     Liabilities"); provided, however, that the Assumed Liabilities shall not
     include any liabilities or obligations to be assumed by DuPont in the
     Merger as provided in the Acquisition Agreement.

4.   License by Seller. Seller hereby grants to Purchaser an exclusive,
     transferable license to the Category II Assets, with right to sublicense,
     to make, have made, import, use, and sell product derived from the Category
     II Assets, worldwide, for every field of use outside of CEDUI. Seller also
     grants to Purchaser the right to file and prosecute divisional applications
     for patent claims relating solely to fields of use outside of CEDUI arising
     from patent applications included within Category II Assets, provided that
     Purchaser will be solely responsible for all costs and expenses incurred in
     connection with such filing and prosecution and further provided that
     Purchaser will have no right to practice, transfer, license, or otherwise
     exploit any patents issuing from such applications within CEDUI. Seller
     expressly retains all rights to the Category II Assets within CEDUI,
     including, without limitation, all rights relating to the product
     Definity(R), all related products (including, without limitation, MRX-421A1
     and MRX-132), all back-up products, next-generation products, and
     improvements thereto.

                                        2

<PAGE>

5.   License by Purchaser. Upon assignment of the Category III Assets, Purchaser
     grants to Seller an exclusive, transferable license to the Category III
     Assets, with right to sublicense, to make, have made, import, use, and sell
     products derived from the Category III Assets, worldwide, within CEDUI.
     Purchaser expressly retains all rights to the Category III Assets outside
     CEDUI.

6.   Seller's Right of First Negotiation to Purchaser's Products. If Purchaser
     develops products or technology in the area of thrombus imaging or
     sonothrombolysis, (collectively, "New Product"), Purchaser will offer to
     Seller an exclusive license to the New Product for development and
     commercialization before offering the New Product to any third party for
     license. In connection therewith, Purchaser will provide Seller with all
     relevant information requested by Seller and reasonably available to
     Purchaser concerning the New Product. Seller will then have ninety (90)
     days within which to make an offer for the New Product. If Seller makes
     such an offer, the parties will negotiate promptly and in good faith to
     arrive at an agreement. If the parties fail to reach such an agreement
     within a reasonable period, Purchaser may assign, license, or otherwise
     transfer rights in the New Product to a third party, but only on terms that
     are, on balance, not less favorable to Purchaser than the last written
     offer of Seller, as reasonably determined by Purchaser, or may pursue
     commercial development of the New Product on its own, at Purchaser's
     election.

7.   Representations and Warranties.

     a.   By Seller. Seller represents and warrants as follows:

          (i)  Seller is the sole owner of the Category II Assets and Category
               III Assets and, subject to any limited rights that the U.S.
               government might have, has the legal authority to assign the
               Category III Assets and to license the Category II Assets to
               Purchaser and otherwise to enter into and perform all of its
               obligations set forth herein;

          (ii) all corporate and other formalities necessary to authorize
               execution, delivery and performance of this Agreement (and all
               other documents executed and delivered in connection herewith) on
               behalf of Seller have been taken; and

     Seller makes no other warranties, express or implied, except as expressly
set forth in this Agreement. In particular, and without limitation, Seller makes
no implied or express warranties of noninfringement or validity or any other
representation or warranty whatsoever regarding Patents or Product.

     b.   By Purchaser. Purchaser represents and warrants as follows:

          (i)  Purchaser has the legal authority to accept the assignment of
               Category III Assets and the license to Category II Assets granted
               hereunder and otherwise to perform all of its obligations set
               forth herein;

                                        3

<PAGE>

          (ii) all LLC and other formalities necessary to authorize execution,
               delivery and performance of this Agreement (and all other
               documents executed and delivered in connection herewith) on
               behalf of Purchaser have been taken.

Purchaser makes no other warranties, express or implied, except as expressly set
forth in this Agreement. In particular, and without limitation, Purchaser makes
no implied or express warranties of noninfringement or validity or any other
representation or warranty whatsoever regarding Patents or Product.

8.   Intellectual Property Protection.

     a.   Claim of Infringement. If Purchaser discovers that a third party
          claims that practice of the Category II Assets infringes a patent or
          other intellectual property right of such third party, then Purchaser
          will promptly so notify Seller and Seller shall have sole authority to
          defend against or settle any such claim of infringement, provided that
          no settlement will impair Purchaser's license granted by Section 4
          above. If Seller discovers that a third party claims that practice of
          the Category III Assets infringes a patent or other intellectual
          property right of such third party, then Seller will promptly so
          notify Purchaser and Purchaser shall have sole authority to defend
          against or settle any such claim of infringement, provided that no
          settlement will impair Seller's license granted by Section 5 above.

     b.   Infringement of Patents. If either party becomes aware that a third
          party is or may be infringing the Patents, it shall promptly so notify
          the other party. If the infringement related to Category II Assets,
          Seller shall have authority to pursue a claim for infringement. If
          Seller fails to resolve such infringement or institute an infringement
          action against the third party within one hundred twenty (120) days
          after Seller becomes aware of the infringement, Seller will assign its
          rights to pursue the infringement to Purchaser. If there is
          infringement related to Category III Assets, Purchaser shall have
          authority to pursue a claim for infringement. If Purchaser fails to
          resolve such infringement or institute an infringement action against
          the third party within one hundred twenty (120) days after Purchaser
          becomes aware of the infringement, then Purchaser shall assign its
          rights to pursue the infringement to Seller.

9.   Claim of Infringement of Sonus Patents. Notwithstanding anything to the
     contrary contained in Section 8 above, the provisions of this Section 9
     will apply to and govern any claim asserted (whether by litigation or
     otherwise) by Sonus Pharmaceuticals, Inc. and/or its licensees or assignees
     (collectively, "Sonus") within five years of the date of this Agreement
     that Seller's manufacture or sale of the product known as Definity(R)
     infringes a patent or other intellectual property right of Sonus (a "Sonus
     infringement claim"). If Seller receives a Sonus infringement claim, it
     will promptly so notify Purchaser, and the parties will proceed as follows:

                                        4

<PAGE>

     a.   Seller will keep Purchaser informed of developments relevant to the
          Sonus claim and will consider Purchaser's recommendations for
          proceeding, although Seller will have the final authority;

     b.   Seller will use all commercially reasonable efforts to defeat or
          resolve a Sonus claim, including but not limited to cross licensing
          its diagnostic technology to Sonus;

     c.   Purchaser will use all commercially reasonable efforts in cooperation
          with Seller and in support of Seller's efforts, including the
          commitment of all reasonable amounts of Dr. Evan Unger's time, subject
          to reimbursement by Seller of Purchaser's out of pocket costs (which
          will not include the value of Dr. Unger's time);

     d.   At Seller's election, if these commercially reasonable efforts fail to
          resolve the Sonus claim and Seller believes it is at substantial risk
          of losing the ability to manufacture or sell Definity(R) in a
          commercially significant geographic market, Purchaser will grant to
          Seller a transferable covenant not to sue Sonus for infringement of
          Purchaser's Category III assets to the extent necessary to allow Sonus
          to manufacture and sell its therapeutic products, provided that Seller
          receives a reciprocal covenant from Sonus, which Seller will then
          transfer to Purchaser;

     e.   The covenant referenced in Paragraph 9.d above will be drawn as
          narrowly as possible to allow Sonus to manufacture and sell Sonus's
          therapeutic products, and will not be construed as a license to allow
          Sonus to manufacture or sell products developed by Purchaser or to
          grant Sonus and rights in any safety or efficacy data developed by
          Purchaser relating to those products; and

     f.   If Seller directs Purchaser to provide a covenant pursuant to
          Paragraph 9.d, Seller will pay Purchaser the sum of $1.5 million in
          partial compensation for Purchaser's delivery of the covenant.

10.  Indemnification.

     a.   Seller shall indemnify, defend, and hold Purchaser harmless from any
          and all claims, demands, lawsuits, and associated costs and expenses,
          including reasonable attorneys' fees and cost of settlement, arising
          out of Seller's manufacture, promotion, marketing, and sale of
          products derived from or based on Category III Assets; provided,
          however, that Seller shall not be obligated to indemnify, defend, and
          hold Purchaser harmless where the claim, demand, lawsuit, and
          associated costs and expenses, including reasonable attorneys' fees
          and cost of settlement arises out of the breach of this Agreement by
          Purchaser and further provided that Purchaser promptly notifies Seller
          upon becoming aware of any such claims. Seller shall have the right to
          conduct the defense of any such claim but if Seller fails after
          reasonable notice from Purchaser to conduct such defense, Purchaser
          shall have the right to do so and Seller will reimburse

                                        5

<PAGE>

          Purchaser for all reasonable costs and expenses of defending the
          action, including attorneys' fees and costs of settlement.

     b.   Purchaser shall indemnify, defend, and hold Seller harmless from any
          and all claims, demands, lawsuits, and associated costs and expenses,
          including reasonable attorneys' fees and cost of settlement, arising
          out of Purchaser's manufacture, promotion, marketing, and sale of
          products derived from or based on Category II Assets; provided
          however, that Purchaser shall not be obligated to indemnify, defend,
          and hold Seller harmless where the claim, demand, lawsuit, and
          associated costs and expenses, including reasonable attorneys' fees
          and cost of settlement arises out of the breach of this Agreement by
          Seller and further provided that Seller promptly notifies Purchaser
          upon becoming aware of any such claims. Purchaser shall have the right
          to conduct the defense of any such claim but if Purchaser fails after
          reasonable notice from Seller to conduct such defense, Seller shall
          have the right to do so and Purchaser will reimburse Seller for all
          reasonable costs and expenses of defending the action, including
          attorneys' fees and costs of settlement.

11.  Rights to Improvements in Product or Manufacturing. All assignments and
     licenses hereunder include such rights to improvements as Seller has
     received or is entitled to receive from DuPont pursuant to Section 5 of the
     Assignment and License Agreement dated October 23, 1995, through the date
     of the Closing of the Acquisition Agreement, to the extent that such
     improvements apply outside the field of CEDUI.

12.  Maintenance and Prosecution of Patents

     a.   Seller may elect not to prosecute or maintain a patent within the
          Category II Assets if it reasonably concludes that such patent has no
          significant value to Seller within the field of CEDUI. In that event,
          it will so notify Purchaser. Purchaser will, within ninety (90) days
          of receipt of such notice, notify Seller whether it wishes to acquire
          the patent from Seller. During this ninety (90) day period, Seller
          will take any action necessary to continue to prosecute or maintain
          the patent. Purchaser will reimburse Seller for its out-of-pocket
          costs incurred in such actions. Upon notice by Purchaser that it
          wishes to acquire the patent from Seller, Seller will assign the
          patent to Purchaser, transfer any files or other documents relating to
          the patent to Purchaser, and Purchaser will thereafter be solely
          responsible for prosecution or maintenance of the Patent, including
          all costs associated therewith. Seller agrees to execute any
          additional documents necessary to perfect Purchaser's rights to the
          patent. Purchaser agrees that, upon transfer of the patent to
          Purchaser, it will not assert any claim related to such paten against
          Seller. If no notice is received by Seller within the ninety (90)
          period, Seller will abandon the patent.

     b.   Purchaser may elect not to prosecute or maintain a patent within the
          Category III Assets if it reasonably concludes that such patent has no
          significant value to Purchaser outside the field of CEDUI. In that
          event, it will so notify Seller. Seller will, within ninety (90) days
          of receipt of such notice, notify Purchaser

                                        6

<PAGE>

          whether wishes to acquire the patent from Purchaser. During this
          ninety (90) day period, Purchaser will take any action necessary to
          continue to prosecute or maintain the patent. Seller will reimburse
          Purchaser for its out-of-pocket costs incurred in such actions. Upon
          notice by Seller that it wishes to acquire the patent from Purchaser,
          Purchaser will assign the patent to Seller, transfer any files or
          other documents relating to the patent to Seller, and Seller will
          thereafter be solely responsible for prosecution or maintenance of the
          Patent, including all costs associate therewith. Purchaser agrees to
          execute any additional documents necessary to perfect Seller's rights
          to the patent. Seller agrees that, upon transfer of the patent to
          Seller, it will not assert any claim related to such patent against
          Purchaser. If no notice is received by Purchaser within the ninety
          (90) period, Purchaser will abandon the patent.

     H. Further Assurances. At any time, the parties shall execute such
additional instruments, provide such additional information and take such
additional action as may be reasonably requested by the other party to confirm
or perfect title to any property transferred hereunder or otherwise to carry out
the intent and purposes of this Agreement.

     I. Arizona Law. The laws of the State of Arizona, without regard to its
conflict of laws principles, shall govern the validity of this Agreement, the
construction of its terms, and the interpretation of the rights and duties of
the Managers and Members. Pima County, Arizona shall be the exclusive proper
venue for any action brought under this Agreement.

     J. Counterparts. This Agreement may be executed in two or more
counterparts, and by the different parties hereto in separate counterparts, each
of which when executed shall be deemed to be an original, but all of which taken
together shall constitute one and the same instrument.

     K. Construction. Nothing expressed or implied in this Agreement is intended
to confer upon any person, other than Purchaser and Seller and their respective
successors and assigns, any rights, remedies, obligations or liabilities under
or by reason of this Agreement.

                                        7

<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.

IMARX PHARMACEUTICAL CORP.,             IMARX LLC,
an Arizona corporation                  an Arizona limited liability company

By: /s/ Evan Unger                      By: /s/ Evan Unger
    ---------------------------------       ------------------------------------
    Dr. Evan Unger                          Dr. Evan Unger
Its: President                          Its: Manager

                                        8

<PAGE>

                                    EXHIBIT A
             PHYSICAL ASSETS AND RECEIVABLES AND CATEGORY III ASSETS

                         PHYSICAL ASSETS AND RECEIVABLES

1.   Cash in the amount of $104,012.

2.   All of the right, title and interest of ImaRx in that tangible personal
     property set forth on Schedule 1, attached hereto and incorporated by
     reference herein.

3.   All of the inventories of ImaRx.

4.   All accounts receivable of ImaRx as of the effective date of the Merger,
     including trade accounts receivable.

5.   All amounts receivable from the National Institutes of Health pursuant to a
     grant awarded to ImaRx dated July 29, 1999.

6.   All amounts receivable from employees of ImaRx as of the effective date of
     the Merger.

7.   All rights and privileges in and amounts receivable by ImaRx under that
     certain agreement with BRAACO International and BRAACO Diagnostic Inc.
     dated December 4, 1998.

                               CATEGORY III ASSETS

1.   UNGR 0350

     United States - Pending - 08/942,862 (UNGR 1227)

2.   UNGR 0480

     United States - Pending - 08/741,598 (UNGR 0991), 09/052,075 (UNGR 1283)

3.   UNGR 0570

     United States - Pending - 08/947,305 (UNGR 1223)

4.   UNGR 1172 family

     United States - Pending - USSN 08/929,847 - first Office Action

     Europe - Pending - UNGR 1501 (States: AT, BE, DK, FR, DE, GB, GR, IE, IT,
     LU, NE, ES, SE, CH)

5.   UNGR 1269 family

     United States - Pending - USSN 08/982,829 - first Office Action

                                        9

<PAGE>

                                    EXHIBIT B
                               CATEGORY II ASSETS

1.   UNGR 0019 family

     United States - Issued - 5,088,499 (UNGR-0019), 5,230,882 (UNGR-0095),
     5,352,435 (UNGR-0279), 5,456,901 (UNGR-0574)

     United States - Allowed - 08/665,719 (UNGR-0728), 08/888,426 (UNGR-1190)

     Europe - UNGR 0029, 0628 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, NE,
     ES, SE, CH/LU)

     Japan - UNGR 0043

2.   UNGR 0046

     United States - Issued - 5,205,290 (UNGR-0046), 5,281,408 (UNGR-0295),
     5,456,900 (UNGR-0346), 5,547,656 (UNGR-0664), 5,527,521 (UNGR-0665)

     United States - Pending - 08/878,233 (UNGR-1174)

     United States - Abandoned - UNGR 0875

     Europe - UNGR 0099 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, MO, NE, ES,
     SE, CH/LU)

     Japan - UNGR 0114

3.   UNGR 0048

     United States - Issued - 5,305,757 (UNGR-0299), 5,348,016 (UNGR-0319)

     United States - Pending - 09/000,522

4.   UNGR 0298

     United States - Issued - 5,469,854 (UNGR-0298), 5,715,824 (UNGR-0686)

     United States - Allowed - 08/758,179 (UNGR-0988)

     Europe - UNGR 0448 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, NE, ES, SE,
     CH/LU)

     Japan - UNGR 0466

5.   UNGR 0348

     United States - Issued - 5,542,935 (UNGR-0348)

                                       10

<PAGE>

     United States - Pending - 08/485,998 (UNGR-0692)

     Europe - UNGR 0487 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, NE, ES, SE,
     CH)

     Japan - UNGR 0504

6.   UNGR 0350

     United States - Issued - 5,585,112 (UNGR-0350), 5,853,752 (UNGR-0685)

     Europe - UNGR 0509 (States: AT, BE, DK, FR, DE, GB, GR, IE, IT, LU, NE, ES,
     SE, CH)

     Japan - UNGR 0526

7.   UNGR 0480

     United States - Issued - 5,5773,024 (UNGR-0480)

     Europe - UNGR 0697 (States: AT, BE, DK, FR, DE, GB, GR, IE, IT, LU, NE, ES,
     SE, CH)

     Japan - UNGR 0714

8.   UNGR 0570

     United States - Issued - 5,705,187 (UNGR-0570)

     Europe - UNGR 0889 (States: AT, BE, DK, FI, FR, DE, GB, GR, IE, IT, LU, MO,
     NE, PT, ES, SE, CH)

     Japan - UNGR 0906

9.   UNGR 0571

     United States - Issued - 5,656,211 (UNGR-0571)

     United States - Pending - 08/833,489 (UNGR-1035)

     Europe - UNGR 0815 (States: AT, BE, DK, FI, FR, DE, GB, GR, IE, IT, LU, MO,
     NE, PT, ES, SE, CH)

     Japan - UNGR 0832

10.  UNGR 0725

     United States - Allowed - 08/666,129 (UNGR-0725)

     Europe - UNGR 1009 (States: FR, GB, DE, NE)

                                       11

<PAGE>

     Japan - UNGR 1027

11.  UNGR 0733

     United States - Issued - 5,776,429 (UNGR-0733)

     United States - Pending - 09/026,326 (UNGR 1286)

     Europe - UNGR 1046 (States: AT, BE, DK, FI, FR, DE, GB, GR, IE, IT, LU, MO,
     NE, PT, ES, SE, CH)

     Japan - UNGR 1064

12.  UNGR 1550 family

     United States - Pending - USSN 09/243,640 - awaiting first Office Action;
     not eligible for foreign filing until 2/3/2000

13.  UNGR 0992 and 1030 - Interference applications

14.  UNGR 1032

     United States - Pending - UNGR 1032, 1192

                                       12

<PAGE>

                                    EXHIBIT C
                               ASSUMED LIABILITIES

1.   Promissory Note Payable to the order of Thomas Fritz dated September 30,
     1998.

2.   Promissory Note Payable to Bank One, N.A. dated April 10, 1999.

3.   Master Finance Lease Payable to Zions Credit Corporation dated January 21,
     1999.

4.   All accounts payable by ImaRx as of the effective date of the Merger.

5.   All accrued salaries, bonuses, and deferred employee compensation payable
     by ImaRx as of the effective date of the Merger.

6.   All income, sales, transaction privilege, use, excise, payroll and other
     taxes payable by ImaRx to any government, governmental agency, or
     subdivision thereof, as of the effective date of the Merger.

7.   All other liabilities of ImaRx as of the date of the Merger, other than
     those liabilities specifically retained by ImaRx and accepted by du Pont in
     the Acquisition Agreement, as set forth in Section 3.11 of the Disclosure
     Schedule to the Agreement and Plan of Merger.

                                       13

<PAGE>

            AMENDMENT TO ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT

     THIS AMENDMENT to the Assignment, Assumption and License Agreement dated as
of October 7, 1999 (the "Agreement") by and between IMARX, LLC, an Arizona
limited liability company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an
Arizona corporation ("Seller") is entered into and effective this ___ day of
July, 2000 by and between IMARX THERAPEUTICS, INC., successor in interest to
Purchaser ("ImaRx") and DuPont Contrast Imaging, Inc. ("DuPont"), successor in
interest to Seller. Capitalized terms used but not otherwise defined herein have
the meanings assigned to them in the Agreement.

                                    RECITALS

     A. Purchaser and Seller entered into the Agreement as of October 7, 1999.
Thereafter, Seller was merged into DuPont.

     B. Exhibit A and Exhibit B to the Agreement were incomplete. The parties
now wish to correct this error by amending Exhibit A and Exhibit B to conform to
the parties' original understanding.

     NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Agreement, the parties agree as
follows:

                                    AGREEMENT

1.   Assignment of Assets. Attached hereto is Exhibit E. Exhibit E sets forth
     additional Category III Assets that were intended to be and hereby are
     included in Exhibit A, effective as of the date of the Agreement. DuPont
     will execute any other or further documents reasonably deemed necessary to
     reflect the transfer of the assets set forth in Exhibit E to ImaRx in
     accordance with the terms of the Agreement.

2.   License of Assets. Attached hereto is Exhibit F. Exhibit F sets forth
     additional Category II Assets that were intended to be and hereby are
     included in Exhibit B, effective as of the date of the Agreement. The
     Assets set forth in Exhibit F are subject to the license terms of Paragraph
     4 of the Agreement, effective as of the date of the Agreement.

3.   No Warranty. DuPont believes that it has not assigned, conveyed, licensed
     or otherwise transferred any interest in any asset listed on Exhibit E to
     any other person or entity. DuPont believes that it has not licensed or
     otherwise transferred any interest in any asset listed on Exhibit F that
     would conflict with or be contrary to the exclusive license to ImaRx as
     provided in Paragraph 4 of the Agreement. Notwithstanding anything to the
     contrary, DuPont makes no warranty, express or implied, regarding the
     assets listed on Exhibit E and specifically disclaims any responsibility
     for any action or inaction with respect to the assets, including action or
     inaction with regard to the prosecution of any patents or any other
     protection of any intellectual property embodied or reflected in Exhibit E
     and Exhibit F during the period from the date of the Agreement to the date
     of this Amendment.

                                       -1-

<PAGE>

4.   Continued Effect. Except as amended hereby, the Agreement remains in full
     force and effect.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of __________ the day and year first above written.

DUPONT CONTRAST IMAGING INC,            IMARX THERAPEUTICS, INC.,
a Delaware general partnership          an Arizona corporation

By: /s/ Nicholas L. Teti                By: /s/ Evan C. Unger
    ---------------------------------       ------------------------------------
    Nicholas L. Teti                        Dr. Evan Unger
Its:                                    Its: President
     --------------------------------

                                       -2-

<PAGE>
                                   EXHIBIT E

{ISSUED and PENDING US Patents followed by Foreign Files (if any)}

LUMENHANCE PATENT FAMILIES

WWKMN Docket Series (UNGR 0018 and UNGR 0026)

US 5,143,716; US 5,320,826; US 5,449,508; US 5,525,326; US 5,885,549
US 5,368,840; US 5,658,550; US 5,624,661; US 5,645,816; US 5,681,542
US 5,985,244

Other files:      USSN 07/507,125     (abandoned)
                  USSN 09/198,202     (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0018 and UNGR-0026)

Corresponding to UNGR-0018

UNGR-0050 PCT App. No. PCT/US91/02429
UNGR-0051 EPO Application Number 91908011.9;
   now EP Patent No. 0526503
UNGR-0052 Austria
UNGR-0053 Belgium
UNGR-0054 Denmark
UNGR-0055 France
UNGR-0056 United Kingdom
UNGR-0057 Germany
UNGR-0058 Greece
UNGR-0059 Italy
UNGR-0060 Luxembourg
UNGR-0061 Netherlands
UNGR-0062 Spain
UNGR-0063 Sweden
UNGR-0064 Switzerland
UNGR-0065 Japan App. No. 507878/1991
UNGR-0321 PCT App. No. PCT/US93/09083
UNGR-0322 Australia App. No. 51387/93; now Australia Serial No. 671862
UNGR-0322 Australia App. No. 51387/93;
   now Australia Serial No. 671862
UNGR-0323 Canada App. No. 2,146,986
UNGR-0324 EPO App No. 93922369.9
UNGR-0325 Austria
UNGR-0326 Belgium
UNGR-0327 Denmark

                                      -1-
<PAGE>

UNGR-0328 France
UNGR-0329 Germany
UNGR-0330 Great Britain
UNGR-0331 Greece
UNGR-0332 Ireland
UNGR-0333 Italy
UNGR-0334 Luxembourg
UNGR-0335 Monaco
UNGR-0336 Netherlands
UNGR-0337 Portugal
UNGR-0338 Spain
UNGR-0339 Sweden
UNGR-0340 Switzerland
UNGR-0341 Japan App. No. 510017/1994
UNGR-0670 EPO App. No. No. 95111117.8;
   now European Patent No. 0693288
UNGR-0671 Austria - closed
UNGR-0672 Belgium - closed
UNGR-0673 Denmark - closed
UNGR-0674 France
UNGR-0675 Great Britain
UNGR-0676 Germany
UNGR-0677 Greece - closed
UNGR-0678 Italy
UNGR-0679 Luxembourg - closed
UNGR-0680 Nether1ands
UNGR-0681 Spain
UNGR-0682 Sweden - closed
UNGR-0683 Switzerland
UNGR-0982 Australia App. No. 70480/96;
   now Australia Serial No. 687690

Corresponding to UNGR-0026

UNGR-0194 PCT App. No. PCT/US92/03707
UNGR-0195 Australia App. No. 19005/92;
   now Australian Serial No. 674285
UNGR-0196 Canada App. No. 2,133,746
UNGR-0197 EPO App. No. 92911636.6
UNGR-0198 Austria
UNGR-0199 Belgium
UNGR-0200 Denmark
UNGR-0201 France
UNGR-0202 Germany
UNGR-0203 Great Britain

                                      -2-
<PAGE>

UNGR-0204 Greece
UNGR-0205 Italy
UNGR-0206 Luxembourg
UNGR-0207 Monaco
UNGR-0208 Netherlands
UNGR-0209 Spain
UNGR-0210 Sweden
UNGR-0211 Switzerland
UNGR-0212 Japan App. No. 510977/92

SONORX PATENT FAMILY

WWKMN Docket Series (UNGR 0020)

US 5,420,176; US 5,639,442; US 5,714,528; US 5,714,529; US 5,948,387
US 6,024,939

Pending:          USSN 08/574,373
                  USSN 08/574,371

Other files:      USSN 07/532,213 (abandoned)
                  USSN 07/708,731 (abandoned)
                  USSN 07/969,426 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0020)

UNGR-0070 PCT App. No. PCT/US91/03850
UNGR-0071 Canada App. No. 2,081,560 (abandoned)
UNGR-0072 Australia App. No. 80858/91;
   now Australia Serial No. 650466 (abandoned)
UNGR-0073 EPO App. No. 91910712.8;
   now European Patent No. 0531421 (abandoned)
UNGR-0074 Austria (abandoned)
UNGR-0075 Belgium (abandoned)
UNGR-0076 Denmark (abandoned)
UNGR-0077 France (abandoned)
UNGR-0078 Germany (abandoned)
UNGR-0079 United Kingdom (abandoned)
UNGR-0080 Greece (abandoned)
UNGR-0081 Italy (abandoned)
UNGR-0082 Luxembourg (abandoned)
UNGR-0083 Netherlands (abandoned)

                                      -3-
<PAGE>

UNGR-0084 Spain (abandoned)
UNGR-0085 Sweden (abandoned)
UNGR-0086 Switzerland (abandoned)
UNGR-0087 Japan App. No. 510485/91
UNGR-0482 Australia App. No. 63196/94;
   now Australia Serial No. 671538 (abandoned)
UNGR-0861 EPO App. No. 96104842.8 (abandoned)
UNGR-0862 Austria (abandoned)
UNGR-0863 Belgium (abandoned)
UNGR-0864 Denmark (abandoned)
UNGR-0865 France (abandoned)
UNGR-0866 Great Britain (abandoned)
UNGR-0867 Germany (abandoned)
UNGR-0868 Greece (abandoned)
UNGR-0869 Italy (abandoned)
UNGR-0870 Luxembourg (abandoned)
UNGR-0871 Netherlands (abandoned)
UNGR-0872 Spain (abandoned)
UNGR-0873 Sweden (abandoned)
UNGR-0874 Switzerland (abandoned)
UNGR-0915 Australia App. No. 48195/96;
   now Australia Serial No. 686047 (abandoned)

THERAPEUTIC AEROSOMES FAMILIES

WWKMN Docket Series UNGR 0023, UNGR 0067 and UNGR 0068)

US 5,149,319
US 5,209,720
US 5,580,575; US 5,770,222

Pending:          USSN 09/060,396

Other files:      USSN 07/716,899 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0023, UNGR-0067 and UNGR-0068)

Corresponding to UNGR-0023*

UNGR-0175 - PCT App. No. PCT/US92/03705
UNGR-0176 Australia App. No. 19926/92;
   now Australia Serial No. 678341 (abandoned)
UNGR-0177 Canada App. No. 2,118,016 (abandoned)

                                      -4-
<PAGE>

UNGR-0178 EPO App. No. 92912400.6
UNGR-0179 Austria
UNGR-0180 Belgium
UNGR-0181 Denmark
UNGR-0182 France
UNGR-0183 Germany
UNGR-0184 Great Britain
UNGR-0185 Greece
UNGR-0186 Italy
UNGR-0187 Luxembourg
UNGR-0188 Monaco
UNGR-0189 Netherlands
UNGR-0190 Spain
UNGR-0191 Sweden
UNGR-0192 Switzerland
UNGR-0193 Japan App. No. 519204/93
UNGR-1525 Australia App. No. 91369/98 (abandoned)

*     NOTE: The following foreign applications, although corresponding to the
      U.S. patent application UNGR-0023, were not listed since they contain
      subject matter which you have indicated was transferred to DuPont:

        UNGR-1034, Australia App. No. 12212/97; now Australia Serial No. 694973;
        UNGR-1155 Canada App. No. 2,211,517;
        UNGR-1156 EPO App. No. 97202273.5 (and its corresponding country files
         UNGR-1157 to UNGR-1170);
        UNGR-1171 Japan App. No. 184624/97.

 Corresponding to UNGR-0067

UNGR-0135 PCT App. No. PCT/US92/02610
UNGR-0136 Australia App. No. 21496/92;
   now Australia Serial No. 661701 (abandoned)
UNGR-0137 Canada App. No. 2,110,487 (abandoned)
UNGR-0138 EPO App. No. 92912455.0;
   now European Patent No. 0660687
UNGR-0139 Austria;
   now Austria Patent No. AT E 172625 T1 (abandoned)
UNGR-0140 Belgium (abandoned)
UNGR-0141 Denmark (abandoned)
UNGR-0142 France (abandoned)
UNGR-0143 Germany;

                                      -5-
<PAGE>

   now Germany Patent No. DE 692 27 468 T 2
UNGR-0144 Great Britain
UNGR-0145 Greece;
   now Greece Patent No. 3028600 (abandoned)
UNGR-0146 Italy
UNGR-0147 Luxembourg (abandoned)
UNGR-0148 Monaco (abandoned)
UNGR-0149 Netherlands (abandoned)
UNGR-0150 Spain (abandoned)
UNGR-0151 Sweden (abandoned)
UNGR-0152 Switzerland
UNGR-0153 Japan App. No. 500845/93;
   now Japan Patent No. 3053217

Corresponding to UNGR-0068

UNGR-0154 PCT App. No. PCT/US92/02614
UNGR-0155 Australia App. No. 20238/92;
   now Australia Serial No. 667672
UNGR-0156 Canada App. No. 2,110,490
UNGR-0157 EPO App. No. 92912662.1
UNGR-0158 Austria
UNGR-0159 Belgium
UNGR-0160 Denmark
UNGR-0161 France
UNGR-0162 Germany
UNGR-0163 Great Britain
UNGR-0164 Greece
UNGR-0165 Italy
UNGR-0166 Luxembourg
UNGR-0167 Monaco
UNGR-0168 Netherlands
UNGR-0169 Spain
UNGR-0170 Sweden
UNGR-0171 Switzerland
UNGR-0172 Japan App. No. 500846/93
UNGR-0423 PCT App. No. PCT/US94/05620
UNGR-0424 Australia App. No. 70948/94;
   now Australia Serial No. AU 684088 (abandoned)
UNGR-0425 Canada App. No. 2,164,843 (abandoned)
UNGR-0426 China App. 94192404.1 (abandoned)
UNGR-0427 EPO App. No. 94920019.0
UNGR-0428 Austria
UNGR-0429 Belgium

                                      -6-
<PAGE>

UNGR-0430 Denmark
UNGR-0431 France
UNGR-0432 Germany
UNGR-0433 Great Britain
UNGR-0434 Greece
UNGR-0435 Ireland
UNGR-0436 Italy
UNGR-0437 Luxembourg
UNGR-0438 Monaco
UNGR-0439 Netherlands
UNGR-0440 Portugal
UNGR-0441 Spain
UNGR-0442 Sweden
UNGR-0443 Switzerland
UNGR-0444 Japan App. No. 501807/95

BLOCK MRI COPOLYMERS FAMILY

WWKMN Docket Series (UNGR 0045)

US 5,385,719; US 5,458,127; US 5,517,993

Other files:      USSN 07/765,921 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0045)

UNGR-0235 PCT App. No. PCT/US92/08205
UNGR-0236 Australia App. No. 27524/92;
   now Australia Serial No. 661344
UNGR-0237 Canada App. No. 2,116,357 (abandoned)
UNGR-0238 EPO App. No. 92921259.5 (abandoned)
UNGR-0239 Austria (abandoned)
UNGR-0240 Belgium (abandoned)
UNGR-0241 Denmark (abandoned)
UNGR-0242 France (abandoned)
UNGR-0243 Germany (abandoned)
UNGR-0244 Great Britain (abandoned)
UNGR-0245 Greece (abandoned)
UNGR-0246 Ireland (abandoned)
UNGR-0247 Italy (abandoned)
UNGR-0248 Luxembourg (abandoned)
UNGR-0249 Monaco (abandoned)

                                      -7-
<PAGE>

UNGR-0250 Netherlands (abandoned)
UNGR-0251 Spain (abandoned)
UNGR-0252 Sweden (abandoned)
UNGR-0253 Switzerland (abandoned)
UNGR-0254 Japan App. No. 506396/93

MEMSOMES FAMILY

WWKMN Docket Series (UNGR 0066)

US 5,312,617; US 5,466,438; US 5,624,662 US 5,762,910; US 6,010,682

Other files: USSN 07/704,542 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0066)

UNGR-0214 PCT App. No. PCT/US92/04310
UNGR-0215 Australia App. No. 19987/92;
   now Australia Serial No. 660033 (abandoned)
UNGR-0216 Canada App. No. 2,102,605 (abandoned)
UNGR-0217 EPO App. No. 92912134.1 (abandoned)
UNGR-0218 Austria (abandoned)
UNGR-0219 Belgium (abandoned)
UNGR-0220 Denmark (abandoned)
UNGR-0221 France (abandoned)
UNGR-0222 Great Britain (abandoned)
UNGR-0223 Germany (abandoned)
UNGR-0224 Greece (abandoned)
UNGR-0225 Italy (abandoned)
UNGR-0226 Luxembourg (abandoned)
UNGR-0227 Monaco (abandoned)
UNGR-0228 Netherlands (abandoned)
UNGR-0229 Spain (abandoned)
UNGR-0230 Sweden (abandoned)
UNGR-0231 Switzerland (abandoned)
UNGR-0232 Japan App. No. 500308/93
UNGR-0726 Australia App. No. 30536/95;
   now Australia Serial No. 678724 (abandoned)

 NANOGELS

                                      -8-
<PAGE>

WWKMN Docket Series (UNGR 0089)

US 5,358,702; US 5,976,500

Other files:      USSN 07/794,437 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0089)

UNGR-0259 PCT App. No. PCT/US92/08948
UNGR-0260 Australia App. No. 28940/92;
   now Australia Serial No. 667491(abandoned)
UNGR-0261 Canada App. No. 2,121,681 (abandoned)
UNGR-0262 EPO App. No. 92922870.8 (abandoned)
UNGR-0263 Austria (abandoned)
UNGR-0264 Belgium (abandoned)
UNGR-0265 Denmark (abandoned)
UNGR-0266 France (abandoned)
UNGR-0267 Great Britain (abandoned)
UNGR-0268 Germany (abandoned)
UNGR-0269 Greece (abandoned)
UNGR-0270 Ireland (abandoned)
UNGR-0271 Italy (abandoned)
UNGR-0272 Luxembourg (abandoned)
UNGR-0273 Monaco (abandoned)
UNGR-0274 Netherlands (abandoned)
UNGR-0275 Spain (abandoned)
UNGR-0276 Sweden (abandoned)
UNGR-0277 Switzerland (abandoned)
UNGR-0278 Japan App. No. 509251/93 (abandoned)

AEROCREME

WWKMN Docket Series (UNGR 0343)

US 5,733,572

Pending:          USSN     08/909,157

Other files:      USSN 08/159,674 (abandoned)

FOREIGN -

                                      -9-
<PAGE>

Corresponding to WWKMN Docket Series (UNGR-0343)

UNGR-0547 PCT App. No. PCT/US94/13817
UNGR-0548 Australia App. No. 21850/95 (abandoned)
UNGR-0549 Canada App. No. 2,177,713
UNGR-0550 China App. No. 94194349.6
UNGR-0551 EPO App. No. 95908414.6
UNGR-0552 Austria
UNGR-0553 Belgium
UNGR-0554 Denmark
UNGR-0556 Great Britain
UNGR-0557 Germany
UNGR-0558 Greece
UNGR-0559 Ireland
UNGR-0560 Italy
UNGR-0561 Luxembourg
UNGR-0562 Monaco
UNGR-0563 Netherlands
UNGR-0564 Portugal
UNGR-0565 Spain
UNGR-0566 Sweden
UNGR-0567 Switzerland
UNGR-0568 Japan App. No. 515763/95
UNGR-1549 Australia App. No. 10043/99 (abandoned)

MRI HYBRIDS
(Prosecuted by A. Durando, Esq.)

US 5,407,657*

* Also include foreign equivalents Australia - AU 9524601 and Europe - EPO
  822835

SUNSCREEN

WWKMN Docket Series (UNGR 0469)

US 5,824,312

Other files:      USSN 08/209,531 (abandoned)

                                      -10-
<PAGE>
FOREIGN -

WWKMN Docket Series (UNGR-0469)

No foreign filing corresponding to UNGR-0469

BIOPSY DEVICE

WWKMN Docket Series WNGR 0540)

US 5,628,327; US 6,O 13,035

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0540)

No foreign filing corresponding to UNGR-0540

                                      -11-
<PAGE>
TRANSDUCERDRUG DELIVERY

WWKMN Docket Series fUNGR 06221

US 5,558,092

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0622)

UNGR-0920 PCT App. NO. PCT/US96/07621
UNGR-0921 Australia App. No. 58756/96;
   now Australia Serial No. 711788
UNGR-0922 Canada App. No. 2,220,756 (abandoned)
UNGR-0923 China App. No. 96194441.2 (abandoned)
UNGR-0924 EPO App. NO. 96920466.8
UNGR-0925 Austria
UNGR-0926 Belgium
UNGR-0927 Denmark
UNGR-0928 Finland
UNGR-0929 France
UNGR-0930 Great Britain
UNGR-0931 Germany
UNGR-0932 Greece
UNGR-0933 Ireland
UNGR-0934 Italy
UNGR-0935 Luxembourg
UNGR-0936 Monaco
UNGR-0937 Netherlands
UNGR-0938 Portugal
UNGR-0939 Spain
UNGR-0940 Sweden

                                      -12-
<PAGE>
UNGR-0941 Switzerland
UNGR-0942 Japan App. No. 500706/97
UNGR-1581 Australia App. No. 44448/99

TOMORX

WWKMN Docket Series (UNGR 0477 and 0623)

US 5,736,121
US 5,874,062

Pending:      USSN 081935,601
              USSN 081968,776

Other files:  081247,656 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0477 and UNGR-0623)

Correspondinp to UNGR-0477

UNGR-0599 PCT App. NO. PCTRJS95106499
UNGR-0600 Australia App. No. 26013195;
  now Australia Serial No. 700799; now Australia Patent No. AU-B-26013195
  (abandoned)
UNGR-0601 Canada App. No. 2,188,557 (abandoned)
UNGR-0602 China App. No. 95 193160.1 (abandoned)
UNGR-0603 EPO App. No. 95920616.0 (aandoned)
UNGR-0604 Austria (abandoned)
UNGR-0605 Belgium (abandoned)
UNGR-0606 Denmark (abandoned)
UNGR-0607 France (abandoned)
UNGR-0608 Great Britain (abandoned)
UNGR-0609 Germany (abandoned)
UNGR-0610 Greece (abandoned)
UNGR-0611 Ireland(abandoned)
UNGR-0612 Italy (abandoned)
UNGR-0613 Luxembourg (abandoned)
UNGR-0614 Monaco (abandoned)
UNGR-0615 Netherlands (abandoned)
UNGR-0616 Portugal (abandoned)
UNGR-0617 Spain (abandoned)
UNGR-0618 Sweden (abandoned)
UNGR-0619 Switzerland (abandoned)

                                      -13-
<PAGE>
UNGR-0620 Japan App. No. 530494/95

Corresponding to UNGR-0623

UNGR-0642 PCT App. NO. PCT/US95/06491
UNGR-0643 Australia App. No. 26454/95;
    now Australia Serial No. 709471 (abandoned)
UNGR-0644 Canada App. No. 2,191,079 (abandoned)
UNGR-0645 China App. No. 95 193274.8 (abandoned)
UNGR-0646 EPO App. No. 95921354.7 (abandoned)
UNGR-0647 Austria (abandoned)
UNGR-0648 Belgium (abandoned)
UNGR-0649 Denmark (abandoned)
UNGR-0650 France (abandoned)
UNGR-0651 Great Britain (abandoned)
UNGR-0652 Germany (abandoned)
UNGR-0653 Greece (abandoned)
UNGR-0654 Ireland (abandoned)
UNGR-0655 Italy (abandoned)
UNGR-0656 Luxembourg (abandoned)
UNGR-0657 Monaco (abandoned)
UNGR-0658 Netherlands (abandoned)
UNGR-0659 Portugal (abandoned)
UNGR-0660 Spain (abandoned)
UNGR-0661 Sweden (abandoned)
UNGR-0662 Switzerland (abandoned)
UNGR-0663 Japan App. No. 530490/95

MRI AEROSOMES

WWKMN Docket Series (UNGR 0420)

US 5,922,304

Pending:      USSN 09/272,468

Other files:  USSN 08/212,553 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series KJNGR-0420)

UNGR-0576 PCT App. NO. PCT/US95/02782
UNGR-0577 Australia - closed

                                      -14-
<PAGE>
UNGR-0578 Canada - closed
UNGR-0579 China - closed
UNGR-0580 EPO App. NO. 95914685.3
UNGR-058 1 Austria - closed
UNGR-0582 Belgium - closed
UNGR-0583 Denhark - closed
UNGR-0584 France
UNGR-0585 Great Britain
UNGR-0586 Germany
UNGR-0587 Ireland - closed
UNGR-0588 Italy - closed
UNGR-0589 Luxembourg - closed
UNGR-0590 Monaco - closed
UNGR-0591 Netherlands - closed
UNGR-0592 Portugal - closed
UNGR-0593 Spain - closed
UNGR-0594 Sweden - closed
UNGR-0595 Switzerland - closed
UNGR-0596 Japan App. No. 523574195
UNGR-0969 Greece - closed
UNGR-0970 Finland - closed

BIOPSY LEVELING DEVICE

WWKMN Docket Series (UNGR 0943)

US 6,030,348

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0943)

No foreign filing corresponding to UNGR-0943

FLUORINATED PRODRUGS

WWKMN Docket Series (UNGR 1114)

US   6,028,066

FOREIGN -

Correspondinq to WWKMN Docket Series (UNGR-1114)

                                      -15-
<PAGE>
UNGR-1368 PCT App. NO. PCT/US98/07712
UNGR-1370 Australia-closed
UNGR-137 1 Brazil-closed
UNGR- 1372 Canada-closed
UNGR-1373 EPO'App. No. 98915610.4 - closed
UNGR- 1374 Austria-closed
UNGR-1375 Belgium-closed
UNGR-1376 Cyprus-closed
UNGR-1377 Denmark-closed
UNGR-1378 Finland-closed
UNGR-1379 France-closed
UNGR-1380 Great Britain-closed
UNGR- 1381 Germany-closed
UNGR-13 82 Greece-closed
UNGR-1383 Ireland-closed
UNGR-1384 Italy-closed
UNGR-1385 Luxembourg-closed
UNGR-1386 Monaco-closed
UNGR-1387 Netherlands-closed
UNGR-1388 Portugal-closed
UNGR-1389 Spain-closed
UNGR-1390 Sweden-closed
UNGR-1391 Switzerland-closed
UNGR- 1392 Japan-closed
UNGR-1393 Argentina App. No. P980102079

OPTOACOUSTIC DEVICE

WWKMN Docket Series WNGR 1278)

US 5,977,538

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-1278)

UNGR-1557 PCT App. NO. PCT/US99/10021
UNGR-1558 EPO App. No. 99921767.2
UNGR-1559 Austria
UNGR-1560 Belgium
UNGR-1561 Cyprus
UNGR-1562 Denmark

                                      -16-
<PAGE>
UNGR-1563 Finland
UNGR-1564 France
UNGR-1565 Great Britain
UNGR-1566 Germany
UNGR-1567 Greece
UNGR-1568 Ireland
UNGR-1569 Italy
UNGR-1570 Luxembourg
UNGR-1571 Monaco
UNGR-1572 Netherlands
UNGR-1573 Portugal
UNGR-1574 Spain
UNGR-1575 Sweden
UNGR-1576 Switzerland
UNGR- 1577 Japan

MRI FOCUSED SURGICAL ULTRASOUND

WWKMN Docket Series WNGR 0476)

US 6,088,613

FOREIGN -

Corresponding to WWKMN Docket Series WNGR-0476)

UNGR-0764 PCT App. NO. PCT/US96/03054
UNGR-0765 Australia App. No. 51844/96 (abandoned)
UNGR-0766 Canada App. No.2,214,855 (abandoned)
UNGR-0767 China App. No. 96192434.9
UNGR-0768 EPO App. NO. 96908679.2
UNGR-0769 Austria
UNGR-0770 Belgium
UNGR-0771 Denmark
UNGR-0772 France
UNGR-0773 Great Britain
UNGR-0774 Germany
UNGR-0775 Greece
UNGR-0776 Ireland
UNGR-0777 Italy
UNGR-0778 Luxembourg
UNGR-0779 Monaco
UNGR-0780 Netherlands

                                      -17-
<PAGE>
UNGR-0781 Portugal
UNGR-0782 Spain
UNGR-0783 Sweden
UNGR-0784 Switzerland
UNGR-0785 Japan App. No. 527700196

SILICON ARNPHIPHILES

WWKMN Docket Series (UNGR 0880)

Pending:  USSN 08/706,824

FOREIGN      -

Corresponding to WWKMN Docket Series (UNGR-0880)

No foreign filing corresponding to UNGR-0880

SONOPORATION/FLUOROGENE

WWKMN Docket Series WNGR 0917)

Pending:      USSN 081841,169

Other files:  USSN 08/640,554 (abandoned)
              USSN 08/785,661 (abandoned)

FOREIGN-

Corresponding to WWKMN Docket Series (UNGR-0917)

UNGR-1122 PCT App. NO. PCT/US97/07237
UNGR-1123 Australia App. No. 27490197
UNGR-1124 Canada App. No. 2,252,617
UNGR-1125 China - closed
UNGR-1126 EPO App. NO. 97921460.8
UNGR-1127 Austria
UNGR-1128 Belgium
UNGR-1129 Denmark
UNGR-1130 Finland
UNGR-1131 France
UNGR-1132 Great Britain
UNGR-1133 Germany
UNGR-1114 Greece

                                      -18-
<PAGE>
UNGR-1135 Ireland
UNGR-1136 Italy
UNGR-1137 Luxembourg
UNGR-1138 Monaco
UNGR-1139 Netherlands
UNGR-1140 Portogal
UNGR-1141 Spain
UNGR-1142 Sweden
UNGR-1143 Switzerland
UNGR-1144 Japan App. No. 539185197
UNGR-1145 Brazil - closed
UNGR-1146 Hungary - closed
UNGR-1147 S. Korea - closed
UNGR-1148 Mexico - closed
UNGR-1149 Norway - closed
UNGR-1150 Russian Federation - closed
UNGR-115 1 Croatia App. No. P970328A
UNGR-1152 Taiwan App. No. 86106635

DRUG DELIVERY TO INFLAMMED TISSUE

WWKMN Docket Series (UNGR 0975)

Pending: USSN 081823,791

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0975)

UNGR-1288 PCT App. NO. PCT/US98/04074
UNGR-1289 Australia
UNGR-1290 Canada
UNGR-1291 China
UNGR-1292 EPO App. NO. 98908866.1
UNGR-1293 Austria
UNGR-1294 Belgium
UNGR-1295 Denmark
UNGR-1296 Finland
UNGR-1297 France
UNGR-1298 Great Britain
UNGR-1299 Germany
UNGR-1300 Greece
UNGR-1301 Ireland

                                      -19-
<PAGE>
UNGR-1302 Italy
UNGR-1303 Luxembourg
UNGR-1304 Monaco
UNGR-1305 Netherlands
UNGR-1306 Portugal
UNGR-1307 Spain
UNGR-1308 Sweden
UNGR-1309 Switzerland
UNGR-1310 Japan App. No. 533386198
UNGR-1311 S. Korea

CHARGED LIPID AGGREGATES

WWKMN Docket Series (UNGR 0976)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0976)

UNGR-1312 Argentina App. No. P980101234
UNGR-1313 PCT App. NO. PCT/US98/03632
UNGR-1314 Australia
UNGR-1315 Brazil
UNGR-1316 Canada
UNGR-1317 China
UNGR-1318 EPO App. NO. 98906695.6
UNGR-1319 Austria
UNGR-1320 Belgium
UNGR-1321 Denmark
UNGR-1322 Finland
UNGR-1323 France
UNGR-1324 Great Britain
UNGR-1325 Germany
UNGR-1326 Greece
UNGR-1327 Ireland
UNGR-1328 Italy
UNGR-1329 Luxembourg
UNGR-1330 Monaco
UNGR-1331 Netherlands
UNGR-1332 Portugal
UNGR-1333 Spain

                                      -20-
<PAGE>
UNGR-1334 Sweden
UNGR-1335 Switzerland
UNGR-1336 Japan
UNGR-1337 S. Korea

OXYGEN DELIVERY

WWKMN Docket Series (UNGR 0999)

Pending:  USSN 081877,826

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-0999)

UNGR-1454 PCT App. NO. PCTPUS98/12011
UNGR-1455 Canada - closed
UNGR-1456 EPO App. NO. 98928973.1
UNGR-1457 Austria
UNGR-1458 Belgium
UNGR-1459 Cyprus
UNGR-1460 Denmark
UNGR-1461 Finland
UNGR-1462 France
UNGR-1463 Great Britain
UNGR-1464 Germany
UNGR-1465 Greece
UNGR-1466 Ireland
UNGR-1467 Italy
UNGR-1468 Luxembourg
UNGR-1469 Monaco
UNGR-1470 Netherlands
UNGR-1471 Portugal
UNGR-1472 Spain
UNGR-1473 Sweden
UNGR-1474 Switzerland
UNGR-1475 Japan-closed

STEROID PRODRUGS

WWKMN Docket Series (UNGR 1003)

Pending:    USSN 08/85 1,780

                                      -21-
<PAGE>
USSN 09/496,761

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-1003)

UNGR-1342 PCT App. NO. PCT/US98/07492
UNGR-1344 Australia - closed
UNGR-1345 Brazil - closed
UNGR-1346 Canada - closed
UNGR-1347 EPO App. No. 98915571.8 - closed
UNGR-1348 Austria - closed
UNGR-1349 Belgium - closed
UNGR-1350 Cyprus - closed
UNGR-1351 Denmark - closed
UNGR-1352 Finland - closed
UNGR-1353 France - closed
UNGR-1354 Great Britain - closed
UNGR-1355 Germany - closed
UNGR-1356 Greece - closed
UNGR-1357 Ireland - closed
UNGR-1358 Italy - closed
UNGR-1359 Luxembourg - closed
UNGR-1360 Monaco - closed
UNGR- 136 1 Netherlands - closed
UNGR-1362 Portugal - closed
UNGR-1363 Spain - closed
UNGR-1364 Sweden - closed
UNGR-1365 Switzerland - closed
UNGR-1366 Japan - closed
UNGR-1367 Argentina App. No. P980102078 (abandoned)

                                      -22-
<PAGE>
SOLID MATRIX DRUGS

WWKMN Docket Series (UNGR 1394)
Pending:      USSN 09/075,477

Other files:  USSN 60/046,379 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-1394)

UNGR-1425 PCT APP. NO. PCT/US98/09570
UNCR-1326 Australia - closed

                                      -23-
<PAGE>
UNGR-1427 Brazil - closed
UNGR-1428 Canada - closed
UNGR-1429 China - closed
UNGR-1430 EPO App. No. 98921109.9
UNGR-1431 Austria - closed
UNGR-1432 Belgium - closed
UNGR-1433 Cyprus - closed
UNGR-1434 Denmark - closed
UNGR-1435 Finland - closed
UNGR-1436 France
UNGR-1437 Great Britain
UNGR- 1438 Germany
UNGR-1439 Greece - closed
UNGR-1440 Ireland - closed
UNGR-1441 Italy
UNGR-1442 Luxembourg - closed
UNGR-1443 Monaco - closed
UNGR- 1444 Netherlands
UNGR-1445 Portugal - closed
UNGR-1446 Spain - closed
UNGR- 1447 Sweden - closed
UNGR-1448 Switzerland - closed
UNGR-1449 Japan - closed
UNGR-1450 S. Korea - closed
UNGR-145 1 New Zealand - closed
UNGR-1452 Argentina App. No. P980102217
UNGR-1453 Chile App. No. 1035/98

                                      -24-
<PAGE>
TARGETING FOR DIAGNOSIS OF ATRIAL FIBRILLATION

WWKMN Docket Series (UNGR 1173)

Pending:  USSN 081932,273

FOREIGN     -

Corresponding to WWKMN Docket Series (UNGR-1173)

UNGR-1498 PCT App. NO. PCT/US98/18858
UNGR-1499 Australia - closed
UNGR-1500 Canada - closed
UNGR-150 1 EPO App. NO. 989469 19.2
UNGR-1502 Austria - closed
UNGR-1503 Belgium - closed
UNGR- 1504 Cyprus - closed
UNGR- 1505 Denmark - closed
UNGR-1506 Finland - closed
UNGR-1507 France
UNGR-1508 Great Britain
UNGR- 1509 GermanyUNGR- 1510 Greece - closed
UNGR- 1511 Ireland - closed
UNGR- 1512 Italy
UNGR- 15 13 Luxembourg - closed
UNGR-15 14 Monaco - closed
UNGR- 1515 Netherlands - closed
UNGR-1516 Portugal - closed
UNGR-15 17 Spain - closed
UNGR- 1518 Sweden - closed
UNGR-1519 Switzerland - closed

ULTRASOUND GENE UPREGULATION

WWKMN Docket Series (UNGR 1196)
Pending:    USSN 08/971,540

FOREIGN-

Corresponding to WWKMN Docket Series (UNGR-1196)

UNGR-1526 PCT App. No. PCT/US98/23843
UNGR-I 527 Australia - closed
UNGR- 1528 Canada -  closed

                                      -25-
<PAGE>

UNGR-1529 EPO App. No. 98957720.0 - closed
UNGR-1530 France - closed
UNGR-153 1 Great Britain - closed
UNGR-1532 Germany - closed
UNGR-1533 Japan - closed

OPTOACOUSTIC AGENTS

WWKMN DOCKET SERIES (UNGR 1224)

PENDING: USSN 081993,165

FOREIGN -

UNGR-1536 PCT App. No. PCT/US98/27060
UNGR-1537 Australia
UNGR-1538 EPO App. No. 98964127.9
UNGR-1539 France
UNGR-1540 Great Britain
UNGR-1541 Germany
UNGR-1542 Japan

NUCLEAR LOCALIZATION DRUG DELIVERY

WWKMN DOCKET SERIES WNGR 1229)

PENDING: USSN 091294,623

FOREIGN -

UNGR-1587 EPO
UNGR-1588 France
UNGR-1589 Great Britain
UNGR-1590 Germany
UNGR-1591 Italy

ROBOTIC SONOPORATION AND MULTIMODAL ENERGY APPLICATION

WWKMN DOCKET SERIES (UNGR 1477)

PENDING: USSN 09/291,502

FOREIGN -

                                       26
<PAGE>

Corresponding to WWKMN Docket Series (UNGR-1477)

No foreign filing corresponding to UNGR-1477

INFUSION OF BIOACTIVE AGENTS

WWKMN Docket Series (UNGR 1580)

Pending: USSN 09/413,110

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-1580)

Foreign filing deadline October 6,2000

METHODS FOR QUANTITATING LIGAND BINDING TO THROMBUS (PROVISIONAL)

(A. Durando Prosecution)

Pending: USSN 60/118,551

TARGETED THROMBOLYTICS

(A. Durando Prosecution)

Pending: USSN 091371,193

                                       27
<PAGE>

                                    EXHIBIT F

{ISSUED and PENDING US Patents followed by Foreign Files (if any)}

CATIONIC LIPIDS

WWKMN Docket Series WNGR 0569)

US 5,830,430; US 6,056,938

Pending: USSN 091244,083
         USSN 091540,448

FOREIGN -

Corresponding to WWKMN Docket Series KJNGR-0569)

UNGR-0787 PCT App. NO. PCT/US96/01474
UNGR-0789 Australia App. No. 49 138196 (abandoned)
UNGR-0790 Canada App. No. 2,213,417
UNGR-0791 China App. No, 96192058.0
UNGR-0792 EPO App. NO. 9690535 1.1
UNGR-0793 Austria
UNGR-0794 Belgium
UNGR-0795 Denmark
UNGR-0796 France
UNGR-0797 Great Britain
UNGR-0798 Germany
UNGR-0799 Greece
UNGR-0800 Ireland
UNGR-0801 Italy
UNGR-0802 Luxembourg
UNGR-0803 Monaco
UNGR-0804 Netherlands
UNGR-0805 Portugal
UNGR-0806 Spain
UNGR-0807 Sweden
UNGR-0808 Switzerland
UNGR-0809 Japan App. No. 525700196

ACOUSTICALLY ACTIVE LIPOSPHERES

WWKMN Docket Series NNGR 1338)

Pending: USSN 091075,343

                                      -1-
<PAGE>

Other files: USSN 60/046,379 (abandoned)

FOREIGN -

Corresponding to WWKMN Docket Series (UNGR-1338)

UNGR-1396 PCT App. No. PCT/US98/09569
UNGR-1397 Australia - closed
UNGR-1398 Brazil - closed
UNGR-1399 Canada - closed
UNGR-1400 China - closed
UNGR-1401 EPO App. No. 98926033.6
UNGR-1402 Austria
UNGR-1403 Belgium
UNGR-1404 Cyprus
UNGR-1405 Denmark
UNGR-1406 Finland
UNGR-1407 France
UNGR-1408 Great Britain
UNGR-1409 Germany
UNGR-1410 Greece
UNGR-1411 Ireland
UNGR-1412 Italy
UNGR-1413 Luxembourg
UNGR-1414 Monaco
UNGR-1415 Netherlands
UNGR-1416 Portugal
UNGR-1417 Spain
UNGR-1418 Sweden
UNGR-1419 Switzerland
UNGR-1420 Japan App. No. 549372198
UNGR-142I S. Korea - closed
UNGR-1422 New Zealand - closed
UNGR-1423 Argentina App. No. P980102225
UNGR-1424 Chile App. No. 1034/98

                                      -2-
<PAGE>

UNGR-1400 China - closed
UNGR-1401 EPO App. NO. 98926033.6
UNGR-1402 Austria
UNGR-1403 Belgium
UNGR-1404
UNGR-1405 Denmark
UNGR-1406 Finland
UNGR-1407 France
UNGR-1408 Great Britain
UNGR-1409 Germany
UNGR-1410 Greece
UNGR-1411 Ireland
UNGR-1412 Italy
UNGR-1413 Luxembourg
UNGR-1414 Monaco
UNGR-1415 Netherlands
UNGR-1416 Portugal
UNGR-1417 Spain
UNGR-1418 Sweden
UNGR-1419 Switzerland
UNGR-1420 Japan App. No. 549372198
UNGR-1421 S. Korea - closed
UNGR-1422 New Zealand - closed
UNGR-1423 Argentina App. No. P980102225
UNGR-1424 Chile App. No. 1034/98

                                      -3-
<PAGE>

        SECOND AMENDMENT TO ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT

     THIS AMENDMENT to the Assignment, Assumption and License Agreement dated as
of October 7, 1999 (as amended by the amendment dated July 31, 2000, hereinafter
collectively the "Agreement") by and between IMARX, LLC, an Arizona limited
liability company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an Arizona
corporation ("Seller") is entered into and effective April 1, 2002 by and
between IMARX THERAPEUTICS, INC., successor in interest to Purchaser ("ImaRx")
and Bristol-Myers Squibb Medical Imaging, Inc. ("BMS"), successor in interest to
Seller. Capitalized terms used but not otherwise defined herein have the
meanings assigned to them in the Agreement.

                                    RECITALS

     A. Purchaser and Seller entered into the Agreement as of October 7, 1999.
Thereafter, Seller was merged into DuPont Contrast Imaging, Inc.

     B. DuPont Contrast Imaging, Inc. was acquired by Bristol-Myers Squibb
Company on October 1, 2001 and the name of DuPont Contrast Imaging, Inc. was
changed to Bristol-Myers Squibb Medical Imaging, Inc.

     C. The parties now wish to amend Exhibit A and Exhibit B of the Agreement
to delete certain Category II Assets and to provide for additional Category III
Assets.

     NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Agreement, the parties agree as
follows.

                                    AGREEMENT

     1. Assignment of Assets. Attached hereto is Attachment A. The parties agree
that the assets set forth in Attachment A are Category III Assets, and Exhibit A
is hereby amended to include the assets set forth in Attachment A. BMS will
execute any other or further documents reasonably deemed necessary to reflect
the transfer and assignment of the assets set forth in Attachment A to ImaRx in
accordance with the terms of the Agreement. Exhibit B is hereby amended to
delete the assets set forth in Attachment A.

     2. ImaRx shall have no obligation to prosecute or maintain any asset in
Attachment A either within CEDUI or outside CEDUI, provided however, that prior
to abandoning any asset in Attachment A, ImaRx shall give BMS at least 15
business days written notice of its intention to do so. Upon notice by BMS that
it wishes to acquire any such asset from ImaRx, ImaRx will assign the asset to
BMS, transfer any files or other documents relating to the asset to BMS, and BMS
will thereafter be solely responsible for prosecution or maintenance of the
asset, including

<PAGE>

BMS-ImaRx                              -4-

Second Amendment to Assignment, Assumption and License Agreement

all costs associated therewith. Any such asset assigned to BMS shall be a
Category II Asset subject to the license set forth in Section 4 of the
Agreement, and BMS shall only have rights under such asset within the CEDUI
field of use.

     3. The second sentence of Section 4 of the Agreement is hereby deleted and
replaced by the following:

     Seller also grants to Purchaser the right to file and prosecute divisional,
     continuation and continuation-in-part applications for patent claims
     relating solely to fields of use outside of the CEDUI field of use arising
     from patent applications included within Category II Assets, provided that
     Purchaser will be solely responsible for all costs and expenses incurred in
     connection with such filing and prosecution and further provided that
     Purchaser will have no right to practice, transfer, license, or otherwise
     exploit any patents issuing from such applications within CEDUI. Purchaser
     shall provide notice to the Seller of the filing of any such patent
     application, the filing date and the Category II patent(s) or patent
     application(s) to which such patent application claims priority and
     identify the assignee of such patent application. Where possible, Purchaser
     shall be the assignee of such patent applications (and patents issuing
     thereon), unless such assignment will adversely effect the patent rights
     involved (for example, in the case of a terminal disclaimer). Where
     Purchaser is the assignee, such patent applications (and patents issuing
     thereon) shall be Category III Assets, subject to the license set forth in
     Section 5. Where Seller is the assignee, such patent applications (and
     patents issuing thereon) shall be Category II Assets, subject to the
     foregoing provisions of this Section 4.

<PAGE>

BMS-ImaRx                              -5-

Second Amendment to Assignment, Assumption and License Agreement

     4. All applications for patents filed by ImaRx as of the date of this
Amendment pursuant to Section 4 of the Agreement which are Category III assets
are identified in Attachment C hereof.

     5. No Warranty. BMS believes that it has not assigned, conveyed, licensed
or otherwise transferred any interest in any asset listed on Attachment A to any
other person or entity. Notwithstanding anything to the contrary, BMS makes no
warranty, express or implied, regarding the assets listed on Attachment A and
specifically disclaims any responsibility for any action or inaction regarding
the prosecution of any patents or any other protection of any intellectual
property embodied or reflected in Attachment A during the period from the date
of the Agreement to the date of this Amendment.

     6. Attachment B. Attached hereto is Attachment B. The assets set forth in
Attachment B are Category II assets. ImaRx agrees to be responsible for the
prosecution and maintenance of the patents and patent applications set forth in
Attachment B, including all costs associated therewith. In the event that ImaRx
wants to abandon any patent or patent application set forth in Attachment B,
ImaRx shall provide BMS at least 15 business days prior written notice of its
intention to do so. BMS shall then have the right to assume responsibility for
the prosecution and maintenance of such patent or patent application and the
costs associated therewith. Upon request by BMS, ImaRx will transfer any files
or other documents relating to such patent or patent application and otherwise
cooperate with BMS to enable BMS to assume responsibility for such patent or
patent application.

     7. Section 5. The following is hereby added to the end of Section 5 of the
Agreement:

Purchaser also grants to Seller the right to file and prosecute divisional,
continuation and continuation-in-part applications for patent claims relating
solely to the CEDUI field of use arising from patent applications included
within Category III Assets, provided that Seller will be solely responsible for
all costs and expenses incurred in connection with such filing and prosecution
and further provided that Seller will have no right to practice, transfer,
license, or otherwise exploit any patents issuing from such applications outside
of the CEDUI field of use. Seller shall provide notice to the Purchaser of the
filing of any such patent application, the filing date and the Category III
patent(s) or patent application(s) to which such patent application claims
priority and identify the assignee of such patent application. Where possible,
Seller shall be the assignee of such patent applications (and patents issuing
thereon), unless such assignment will adversely effect the patent rights
involved (for example, in the case of a terminal disclaimer). Where Seller is
the assignee, such patent applications (and patents issuing thereon) shall be
Category II Assets, subject to the license set forth in Section 4. Where
Purchaser is the assignee, such patent applications (and patents issuing
thereon) shall be Category III Assets, subject to the foregoing provisions of
this Section 5.

     8. Continued Effect. Except as amended hereby, the Agreement remains in
full force and effect.

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed as of the day and year first above written.

BRISTOL-MYERS SQUIBB
MEDICAL IMAGING, INC.

By: /s/ M. Cory Zwerling                        By: /s/ Nina Ossanna
    ----------------------------                   ----------------------------

<PAGE>

BMS-ImaRx                              -6-

Second Amendment to Assignment, Assumption and License Agreement

Its: President                          Its: Sr. Director, Business  Development
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

                                  ATTACHMENT A

BMS-0250 FAMILY

BMS-0253               Brazil Serial No. PI 9609343-9; Filed November 20, 1997
[Formerly UNGR-0811]   (via PCT/US96/07887, Filed June 6, 1996). Method and
FF of BMS-0250         Apparatus for Making Gas-Filled Vesicles of Optimal Size.

BMS-0276               Mexico - Serial No. 9709717; Filed December 5, 1997 (via
[Formerly UNGR-0858]   PCT/US96/07887; Filed June 6, 1996). Method and Apparatus
FF or BMS-0250         for Making Gas-Filled Vesicles of Optimal Size.

BMS-0278               Argentina - Application No. P 96 0102914 (formerly
[Formerly UNGR-0859]   336,835); Filed June 5, 1996. Method and Apparatus for
FF or BMS-0250         Making Gas-Filled Vesicles of Optimal Size.

BMS-0279               Chile Serial No. 986-96, Filed June 5, 1996. Method and
[Formerly UNGR-0860]   Apparatus for Making Gas-Filled Vesicles of Optimal Size.
FF or BMS-0250

                           Attachment A, Page 1 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0441 FAMILY

BMS-0442               EPO - Application No. 98307421.2; Filed September 14,
[Formerly UNGR-1478]   1998. Thermal Preactivation of Gaseous Precursor Filled
FF of BMS-0441         Compositions.

BMS-0443               Austria (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1479]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0444               Belgium (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1480]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0445               Cyprus (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1481]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0446               Denmark (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1482]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0447               Finland (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1483]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0448               France (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1484]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

                           Attachment A, Page 2 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0449               Great Britain (via EPO) - Thermal Preactivation of
[Formerly UNGR-1485]   Gaseous Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0450               Germany (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1486]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0451               Greece (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1487]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0452               Ireland (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1488]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0453               Italy (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1489]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0454               Luxembourg (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1490]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0455               Monaco (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1491]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0456               Netherlands (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1492]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

                           Attachment A, Page 3 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0457               Portugal (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1493]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0458               Spain (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1494]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0459               Sweden (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1495]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0460               Switzerland (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1496]   Precursor Filled Compositions.
EP Designated
Country of BMS-0442

BMS-0003 FAMILY

BMS-0016               European Patent No. 0511273; Granted May 19, 1999.
[Formerly UNGR-0029]   EPO - Application No. 91902857.1; (via PCT/US90/07500;
FF of BMS-0003         Filed December 19, 1990).
                       Liposomes As Contrast Agents For Ultrasonic Imaging And
                       Methods For Preparing The Same.

BMS-0017               Austria - (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0030]   1990) Liposomes As Contrast Agents For Ultrasonic And
EP Designated          Methods For Preparing The Same.
Country of BMS-0016

BMS-0018               Belgium (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0031]   19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated          And Methods For Preparing The Same.
Country of BMS-0016

                           Attachment A, Page 4 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0019               Denmark (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0032]   19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated          And Methods For Preparing The Same.
Country of BMS-0016

BMS-0020               France (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0033]   19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated          And Methods For Preparing The Same.
Country of BMS-0016

BMS-0021               Germany (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0034]   19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated          And Methods For Preparing The Same.
Country of BMS-0016

BMS-0022               Great Britain (via EPO) (Serial No. 91902857.1 filed
[Formerly UNGR-0035]   December 19, 1990.) Liposomes As Contrast Agents For
EP Designated          Ultrasonic And Methods For Preparing The Same.
Country of BMS-0016

BMS-0023               Greece (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0036]   19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated          And Methods For Preparing The Same.
Country of BMS-0016

BMS-0024               Italy (via EPO) (Serial No. 91902857.1 filed December 19,
[Formerly UNGR-0037]   1990.) Liposomes As Contrast Agents For Ultrasonic And
EP Designated          Methods For Preparing The Same.
Country of BMS-0016

BMS-0025               Luxembourg (via EPO) (Serial No. 91902857.1 filed
[Formerly UNGR-0038]   December 19, 1990.) Liposomes As Contrast Agents For
EP Designated          Ultrasonic And Methods For Preparing The Same.
Country of BMS-0016

BMS-0026               Netherlands (via EPO) (Serial No.91902857.1; Filed
[Formerly UNGR-0039]   December 19, 1990.) Liposomes As Contrast Agents For
EP Designated          Ultrasonic And Methods For Preparing The Same.
Country of BMS-0016

                           Attachment A, Page 5 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0027               Spain (via EPO) (Serial No. 91902857.1; Filed December
[Formerly UNGR-0040]   19, 1990.) Liposomes as Contrast Agents for Ultrasonic
EP Designated          and Methods for Preparing the Same.
Country of BMS-0016

BMS-0028               Sweden (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0041]   19, 1990.) Liposomes as Contrast Agents for Ultrasonic
EP Designated          and Methods for Preparing the Same.
Country of BMS-0016

BMS-0029               Switzerland (via EPO) (Serial No.91902857.1; Filed
[Formerly UNGR-0042]   December 19, 1990.) Liposomes as Contrast Agents for
EP Designated          Ultrasonic and Methods for Preparing the Same.
Country of BMS-0016

BMS-0464               Hong Kong Patent No. HK 1013625; Issued April 20, 2000.
[Formerly UNGR-1548]   Hong Kong - Application No. 98114978.0 (via EPO
EP Designated          Application No. 91902857.1) Filed December 23, 1998.
Country of BMS-0016    Liposomes As Contrast Agents For Ultrasonic And Methods
                       For Preparing The Same.

BMS-0439 FAMILY

BMS-0645               U.S. Serial No. 10/113577; Filed April 2, 2002.
CON of BMS-0439        Ultrasound Imaging And Treatment.
[Formerly UNGR-1032]

BMS-0489               EPO - Application No. 97202273.5; Filed May 4, 1992.
[Formerly UNGR-1156]   Methods for Providing Localized Therapeutic Heat to
                       Biological Tissues and Fluids.

BMS-0490               Austria (via EPO) - Methods for Providing Localized
[Formerly UNGR-1157]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0491               Belgium (via EPO) - Methods for Providing Localized
[Formerly UNGR-1158]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

                           Attachment A, Page 6 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0492               Denmark (via EPO) - Methods for Providing Localized
[Formerly UNGR-1159]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0493               France (via EPO) - Methods for Providing Localized
[Formerly UNGR-1160]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0494               Great Britain (via EPO) - Methods for Providing Localized
[Formerly UNGR-1161]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0495               Germany (via EPO) - Methods for Providing Localized
[Formerly UNGR-1162]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0496               Greece (via EPO) - Methods for Providing Localized
[Formerly UNGR-1163]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0497               Italy (via EPO) - Methods for Providing Localized
[Formerly UNGR-1164]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0498               Luxembourg (via EPO) - Methods for Providing Localized
[Formerly UNGR-1165]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0499               Monaco (via EPO) - Methods for Providing Localized
[Formerly UNGR-1166]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

                           Attachment A, Page 7 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0500               Netherlands (via EPO) - Methods for Providing Localized
[Formerly UNGR-1167]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0501               Spain (via EPO) - Methods for Providing Localized
[Formerly UNGR-1168]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0502               Sweden (via EPO) - Methods for Providing Localized
[Formerly UNGR-1169]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0503               Switzerland (via EPO) - Methods for Providing Localized
[Formerly UNGR-1170]   Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489

BMS-0504               Japan (via PCT) - Application No. 184624/97; Filed June
[Formerly UNGR-1171]   26, 1997. Method for Hypothermic Potentiation of Tissue.

BMS-0506               Australian Patent No. 694973; Issued/granted November 19,
[Formerly UNGR-1034]   1998. Australia - Application No. 12212/97; Filed January
                       17, 1997. Method for Hyperthermic Potentiation of
                       Tissues.

BMS-0507               Canada - Application No. 2,211,517; Filed September 9,
[Formerly UNGR-1155]   1997. Methods for Providing Localized Therapeutic Heat to
                       Biological Tissues and Fluids.

BMS-0221 FAMILY

BMS-0224               Russian Federation - Serial No. 97118412, November 5,
[Formerly UNGR-0884]   1997 (via PCT/US96/04208; Filed March 27, 1996). Novel
FF of BMS-0221         Compositions of Lipids and Stabilizing Materials.

BMS-0248               Argentina (via PCT) - Serial No. P96 01 02022; Filed
[Formerly UNGR-0908]   April 2, 1996. Novel Compositions of Lipids and
                       Stabilizing Materials.

                           Attachment A, Page 8 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

FF of BMS-0221

BMS-0249               Chile (via PCT) - Serial No. 528-96, Filed April 3, 1996.
[Formerly UNGR-0909]   Novel Compositions of Lipids and Stabilizing Materials.
FF of BMS-0221

BMS-0343 FAMILY

BMS-0347               EPO Application No. 97920281.9; Filed April 2, 1997 (via
[Formerly UNGR-1046]   PCT/US97/05908). Process for Preparing an Optimally
FF of BMS-0343         Dispersible Lipid Blend.

BMS-0348               Austria (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1047]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0349               Belgium (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1048]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0350               Denmark (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1049]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0351               Finland (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1050]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

                           Attachment A, Page 9 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0352               France (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1051    Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0353               Great Britain (via EPO) - Process for Preparing an
[Formerly UNGR-1052]   Optimally Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0354               Germany (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1053]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0355               Greece (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1054]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0356               Ireland (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1055]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0357               Italy (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1056]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0358               Luxembourg (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1057]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0359               Monaco (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1058]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

                           Attachment A, Page 10 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0360               Netherlands (via EPO) - Process for Preparing an
[Formerly UNGR-1059]   Optimally Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0361               Portugal (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1060]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0362               Spain (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1061]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0363               Sweden (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1062]   Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0364               Switzerland (via EPO) - Process for Preparing an
[Formerly UNGR-1063]   Optimally Dispersible Lipid Blend.
EP Designated
Country of BMS-0347

BMS-0400 FAMILY

DUP-0407               EPO - Application No. 97946447.6; Filed November 3, 1997
[Formerly UNGR-1237]   (via PCT/US97/19900). Novel Compositions of
FF of DUP-0399 and     Perfluorinated Ethers and the Like and Their Use as
DUP-0400               Contrast Media for Diagnostic Imaging and in Other
                       Applications.

DUP-0408               Austria (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1238]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0409               Belgium (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1239]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

                           Attachment A, Page 11 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

DUP-0410               Denmark (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1240]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0411               Finland (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1241]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0412               France (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1242]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0413               Great Britain (via EPO) - Novel Compositions of
[Formerly UNGR-1243]   Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399 and     Contrast Media for Diagnostic Imaging and in Other
DUP-0400               Applications.

DUP-0414               Germany (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1244]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0415               Greece (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1245]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0416               Ireland (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1246]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

DUP-0417               Italy (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1247]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and     Diagnostic Imaging and in Other Applications.
DUP-0400

                           Attachment A, Page 12 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

DUP-0418               Luxembourg (via EPO) - Novel Compositions of
[Formerly UNGR-1248]   Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399         Contrast Media for Diagnostic Imaging and in Other
and DUP-0400           Applications.

DUP-0419               Monaco (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1249]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399         Diagnostic Imaging and in Other Applications.
and DUP-0400

DUP-0420               Netherlands (via EPO) - Novel Compositions of
[Formerly UNGR-1250]   Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399         Contrast Media for Diagnostic Imaging and in Other
and DUP-0400           Applications.

DUP-0421               Portugal (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1251]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399         Diagnostic Imaging and in Other Applications.
and DUP-0400

DUP-0422               Spain (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1252]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399         Diagnostic Imaging and in Other Applications.
and DUP-0400

DUP-0423               Sweden (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1253]   Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399         Diagnostic Imaging and in Other Applications.
and DUP-0400

DUP-0424               Switzerland (via EPO) - Novel Compositions of
[Formerly UNGR-1254]   Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399         Contrast Media for Diagnostic Imaging and in Other
and DUP-0400           Applications.

                           Attachment A, Page 13 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0139 FAMILY

BMS-0140               U.S. Serial No. 08/485,998; Filed June 7, 1995; Novel
[Formerly UNGR-0692]   Therapeutic Delivery Systems. Inventors: Evan C. Unger,
DIV of BMS-0139        Thomas Fritz, Terry Matsunaga, VaradaRajan Ramaswami,
                       David Yellowhair, Guanli Wu.

BMS-0141               PCT Publication WO 94/28874, published December 22, 1994
[Formerly UNGR-0483]   PCT/US94/05633; filed May 19, 1994. Novel Therapeutic
FF of BMS-0139         Delivery Systems. Inventors: Evan Unger, Thomas A. Fritz,
                       Terry Matsunaga, VaradaRajan Ramaswami, David Yellowhair,
                       and Guanli Wu. Also claiming priority from UNGR-0343,
                       U.S. Serial No. 159,674 filed 11/30/93 and U.S. Serial
                       No. 159,687 filed 11/30/93.

BMS-0142               Australia Patent No. AU 696056; Granted May 19, 1994.
[Formerly UNGR-0484]   Australia - Application No. 69537/94, Filed May 19, 1994
FF of BMS-0139         (via PCT/US94/05633 filed May 19, 1994). Novel
                       Therapeutic Delivery Systems. Inventors: Evan C. Unger,
                       Thomas A. Fritz, Terry Matsunaga, VaradaRajan Ramaswami,
                       David Yellowhair, and Guanli Wu.

BMS-0143               Canada Application No. 2,164,846; Filed May 19, 1994.
[Formerly UNGR-0485]   (via PCT/US94/05633 filed 5/19/94. Novel Therapeutic
FF of BMS-0139         Delivery Systems. Inventors: Evan Unger, Thomas A. Fritz,
                       Terry Matsunaga, VaradaRajan Ramaswami, David Yellowhair,
                       and Guanli Wu.

BMS-0162               Japan - Application No. 501811/95 (PCT/US94/05633 filed
[Formerly UNGR-0504]   May 19, 1994). Novel Therapeutic Delivery Systems.
FF of BMS-0139         Inventors: Evan Unger, Thomas A. Fritz, Terry Matsunaga,
                       VaradaRajan Ramaswami, David Yellowhair, and Guanli Wu.

BMS-0467               Australia Patent No. 732440; Issued August 9, 2001.
[Formerly UNGR-1521]   Australia - Application No. 88406/98, Filed October 9,
DIV of UNGR-0484;      1998. Novel Therapeutic Delivery Systems. Inventors: Evan
FF of UNGR-0483;       C. Unger, Thomas A. Fritz, Terry Matsunaga, VaradaRajan
FF of BMS-0139         Ramaswami, David Yellowhair, and Guanli Wu.

                           Attachment A, Page 14 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0280 FAMILY

BMS-0280               U.S. Patent No. 5,997,898; Issued December 7, 1999. U.S.
[Formerly UNGR-0625]   Serial No. 08/465,868 filed June 6, 1995. Stabilized
                       Compositions of Fluorinated Amphiphiles as Contrast
                       Agents for Ultrasound.

BMS-0281               International Publication No. WO 96/07813; Published
[Formerly UNGR-0835]   December 12, 1996.
FF of BMS-0280         PCT - Application No. PCT/US96/07813; Filed May 28, 1996.
                       Gas Filled Liposomes and Gas Bubbles Coated with
                       Perfluorocarbon-Based Surfactants.

BMS-0282               Australia Patent No. 715681; Issued May 25, 2000.
[Formerly UNGR-0837]   Australia - Serial No. 715681 (formerly Application No.
FF of BMS-0280         59360/96; Filed May 28, 1996 (via PCT/US96/07813).
                       Gas Filled Liposomes and Gas Bubbles Coated with
                       Perfluorocarbon-Based Surfactants.

BMS-0284               China - Application No. 961 94248.7; Filed May 28, 1996
[Formerly UNGR-0839]   (via PCT/US96/07813). Gas Filled Liposomes and Gas
FF of BMS-0280         Bubbles Coated with Perfluorocarbon-Based Surfactants.

BMS-0285               EPO - Application No. 96916685.9; Filed May 28, 1996 (via
[Formerly UNGR-0840]   PCT/US96/07813). Gas Filled Liposomes and Gas Bubbles
FF of BMS-0280         Coated with Perfluorocarbon-Based Surfactants.

BMS-0286               Austria (via EPO) - Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0841]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of
BMS-0285

BMS-0287               Belgium (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0842]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of
BMS-0285

                           Attachment A, Page 15 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0288               Denmark (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0843]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0289               France (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0844]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0290               Great Britain (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0845]   Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0291               Germany (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0846]   Coated with Perfluorocarbon-Based Surfactants
FF or BMS-0280

BMS-0292               Greece (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0847]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0293               Ireland (via EPO) - Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0848]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0294               Italy (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0849]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0295               Luxembourg (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0850]   Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

                           Attachment A, Page 16 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0296               Monaco (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0851]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0297               Netherlands (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0852]   Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0298               Portugal (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0853]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0299               Spain (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0854]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0300               Sweden (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0855]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0301               Switzerland (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0856]   Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0302               Japan - Application No. 500770/97; Filed May 28, 1996
[Formerly UNGR-0857]   (via PCT/US96/07813). Gas Filled Liposomes and Gas
FF of BMS-0280         Bubbles Coated with Perfluorocarbon-Based Surfactants.

BMS-0303               Finland (via EPO) - Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0971]   Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285

BMS-0306 FAMILY

BMS-0307               U.S. Serial No. 09/218,660; Filed December 22, 1998.

                           Attachment A, Page 17 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

[Formerly UNGR-1520]   Novel Targeted Compositions for Diagnostic and
                       Therapeutic Use.

BMS-0308               International Publication No. WO 96/40285; Published
[Formerly UNGR-0945]   December 19, 1996. PCT - Serial No. PCT/US96/09938; Filed
FF of BMS-0306         June 6, 1996. Novel Targeted Compositions for Diagnostic
                       and Therapeutic Use.

BMS-0309               China - Application No. 96 1 94499.4; Filed June 6, 1996
[Formerly UNGR-0946]   (via PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306         Diagnostic and Therapeutic Use.

BMS-0310               Australia Patent No. 709562; Issued December 16, 1999.
[Formerly UNGR-0947]   Australia - Serial No. 709562 (formerly Application No.
FF of BMS-0306         62703/96); Filed June 6, 1996 (via PCT Serial No.
                       PCT/US96/09938). Novel Targeted Compositions for
                       Diagnostic and Therapeutic Use.

BMS-0311               Canada - Application No. 2,218,541; Filed June 6, 1996
[Formerly UNGR-0948]   (via PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306         Diagnostic and Therapeutic Use.

BMS-0312               EPO - Application No. 96921486.5; Filed June 6, 1996 (via
[Formerly UNGR-0949]   PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306         Diagnostic and Therapeutic Use.

BMS-0313               Austria (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0950]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

                           Attachment A, Page 18 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0314               Belgium (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0951]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0315               Denmark (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0952]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0316               Finland (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0953]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0317               France (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0954]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0318               Great Britain (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0955]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0319               Germany (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0956]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0320               Greece (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0957]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0321               Ireland (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0958]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

                           Attachment A, Page 19 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0322               Italy (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0959]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0323               Luxembourg (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0960]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0324               Monaco (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0961]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0325               Netherlands (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0962]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0326               Portugal (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0963]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0327               Spain (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0964]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0328               Sweden (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0965]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

BMS-0329               Switzerland (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0966]   Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312

                           Attachment A, Page 20 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0330               Japan - Application No. 502099/97; Filed June 6, 1996
[Formerly UNGR-0967]   (via PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306         Diagnostic and Therapeutic Use.

BMS-0463 FAMILY

BMS-0463               U.S. Serial No.09/243,640; Filed February 3, 1999. Novel
[Formerly UNGR-1550]   Methods of Imaging and Treatment with Targeted
                       Compositions.

BMS-0488               International Publication No. WO 00/45856; Published
FF of BMS-0463         August 10, 2000. PCT - Application No. PCT/US00/02620;
                       Filed February 2, 2000. Novel Methods of Imaging and
                       Treatment with Targeted Compositions.

BMS-0597               Australia Application No. 35866/00 (via PCT/US00/02620;
FF of BMS-0463;        Filed February 2, 2000). Novel Methods of Imaging and
BMS-0462               Treatment with Targeted Compositions. Inventors: Evan C.
                       Unger and Yunqiu Wu.

BMS-0598               Canada Application No. 2,362,200 (via PCT/US00/02620;
FF of BMS-0463;        Filed February 2, 2000). Novel Methods of Imaging and
BMS-0462               Treatment with Targeted Compositions. Inventors: Evan C.
                       Unger and Yunqiu Wu.

BMS-0599               EPO Application No. 00914480.9 (via PCT/US00/02620; Filed
FF of BMS-0463;        February 2, 2000). Novel Methods of Imaging and Treatment
BMS-0462               with Targeted Compositions. Inventors: Evan C. Unger and
                       Yunqiu Wu.

BMS-0600               Austria (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463;        with Targeted Compositions. Inventors: Evan C. Unger and
BMS-0462               Yunqiu Wu.

BMS-0601               Belgium (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463;        with Targeted Compositions. Inventors: Evan C. Unger and
BMS-0462               Yunqiu Wu.

BMS-0602               Cyprus (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463;        with Targeted Compositions. Inventors: Evan C. Unger and
BMS-0462               Yunqiu Wu.

                           Attachment A, Page 21 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0603          Denmark (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0604          Finland (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0605          France (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0606          Great Britain (via EPO). Novel Methods of Imaging and
FF of BMS-0463;   Treatment with Targeted Compositions. Inventors: Evan C. Unger
BMS-0462          and Yunqiu Wu.

BMS-0607          Germany (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0608          Greece (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0609          Ireland (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0610          Italy (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

BMS-0611          Luxembourg (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463;   with Targeted Compositions. Inventors: Evan C. Unger and
BMS-0462          Yunqiu Wu.

BMS-0612          Monaco (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463;   Targeted Compositions. Inventors: Evan C. Unger and Yunqiu Wu.
BMS-0462

                           Attachment A, Page 22 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0613               Netherlands (via EPO). Novel Methods of Imaging and
FF of BMS-0463;        Treatment with Targeted Compositions. Inventors: Evan C.
BMS-0462               Unger and Yunqiu Wu.

BMS-0614               Portugal (via EPO). Novel Methods of Imaging and
FF of BMS-0463;        Treatment with Targeted Compositions. Inventors: Evan C.
BMS-0462               Unger and Yunqiu Wu.

BMS-0615               Spain (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463;        with Targeted Compositions. Inventors: Evan C. Unger and
BMS-0462               Yunqiu Wu.

BMS-0616               Sweden (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463;        with Targeted Compositions. Inventors: Evan C. Unger and
BMS-0462               Yunqiu Wu.

BMS-0617               Switzerland (via EPO). Novel Methods of Imaging and
FF of BMS-0463;        Treatment with Targeted Compositions. Inventors: Evan C.
BMS-0462               Unger and Yunqiu Wu.

BMS-0533 FAMILY

BMS-0538               Canada - Application No. 2,213,417 (via PCT Serial No.
[Formerly UNGR-0790]   PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533         Lipids and The Use Thereof.

BMS-0539               China - Serial No. 96192058.0 (via PCT Serial No.
[Formerly UNGR-0791]   PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533         Lipids and The Use Thereof.

BMS-0540               EPO- Serial No. 96905351.1 (via PCT Serial No.
[Formerly UNGR-0792]   PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533         Lipids and The Use Thereof.

BMS-0541               Austria (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0793]   Thereof.
FF of BMS-0533

BMS-0542               Belgium (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0794]   Thereof.
FF of BMS-0533

                           Attachment A, Page 23 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0543               Denmark (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0795]   Thereof.
FF of BMS-0533

BMS-0544               France (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0796]   Thereof.
FF of BMS-0533

BMS-0545               Great Britain (via EPO). Novel Cationic Lipids and The
[Formerly UNGR-0797]   Use Thereof.
FF of BMS-0533

BMS-0546               Germany (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0798]   Thereof.
FF of BMS-0533

BMS-0547               Greece (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0799]   Thereof.
FF of BMS-0533

BMS-0548               Ireland (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0800]   Thereof.
FF of BMS-0533

BMS-0549               Italy (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0801]   Thereof.
FF of BMS-0533

BMS-0550               Luxembourg (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0802]   Thereof.
FF of BMS-0533

BMS-0551               Monaco (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0803]   Thereof.
FF of BMS-0533

BMS-0552               Netherlands (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0804]   Thereof.
FF of BMS-0533

                           Attachment A, Page 24 of 27
<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0553               Portugal (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0805]   Thereof.
FF of BMS-0533

BMS-0554               Spain (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0806]   Thereof.
FF of BMS-0533

BMS-0555               Sweden (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0807]   Thereof.
FF of BMS-0533

BMS-0556               Switzerland (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0808]   Thereof.
FF of BMS-0533

BMS-0557               Japan - Application No. 525700/96 (via PCT Serial No.
[Formerly UNGR-0809]   PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533         Lipids and The Use Thereof.

BMS-0558 FAMILY

BMS-0558               U.S. Serial No. 09/075,343; Filed May 11, 1998;
[Formerly UNGR-1338]   Confirmation No. 3547. Novel Acoustically Active Drug
Based on UNGR-1118     Delivery Systems. Inventor: Evan C. Unger.

BMS-0559               International Publication No. WO 98/51284; Published
[Formerly UNGR-1396]   November 19, 1998. PCT - PCT/US98/09569; Filed May 12,
FF of BMS-0558         1998. Novel Acoustically Active Drug Delivery Systems.
                       Inventor: Evan C. Unger.

BMS-0564               EPO Application No. 98926033.6 (via PCT/US98/09569; Filed
[Formerly UNGR-1401]   May 12, 1998) - Novel Acoustically Active Drug Delivery
FF of BMS-0558         Systems. Inventor: Evan C. Unger.

BMS-0565               Austria (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1402]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

                           Attachment A, Page 25 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0566               Belgium (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1403]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0567               Cyprus (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1404]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0568               Denmark (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1405]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0569               Finland (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1406]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0570               France (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1407]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0571               Great Britain (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1408]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0572               Germany (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1409]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0573               Greece (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1410]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0574               Ireland (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1411]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0575               Italy (via EPO) - Novel Acoustically Active Drug Delivery
[Formerly UNGR-1412]   Systems. Inventor: Evan C. Unger.
FF of BMS-0558

                           Attachment A, Page 26 of 27

<PAGE>

Attachment A                                BMS-ImaRx Second Amendment Agreement

BMS-0576               Luxembourg (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1413]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0577               Monaco (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1414]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0578               Netherlands (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1415]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0579               Portugal (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1416]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0580               Spain (via EPO) - Novel Acoustically Active Drug Delivery
[Formerly UNGR-1417]   Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0581               Sweden (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1418]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

BMS-0582               Switzerland (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1419]   Delivery Systems. Inventor: Evan C. Unger.
FF of BMS-0558

                           Attachment A, Page 27 of 27
<PAGE>

Attachment B                                BMS-ImaRx Second Amendment Agreement

                                  ATTACHMENT B

BMS-0596               U.S. Serial No. 09/901,934; Filed July 10, 2001. Gas
CON of BMS-0093        Filled Liposomes and their Use as Ultrasonic Contrast
                       Agents. Inventors: Evan C. Unger, Guanli Wu

BMS-0222               U.S. Serial No. 08/947,305; Filed October 8, 1997; Novel
[Formerly UNGR-1223]   Compositions of Lipids and Stabilizing Materials.
DIV of BMS-0221

BMS-0139               U.S. Patent No. 5,542,935; Issued August 6, 1996.
[Formerly UNGR-0348]   U.S. Serial No. 08/160,232; Filed November 30, 1993.
                       Novel Therapeutic Delivery Systems Related Applications.
                       Inventors: Evan C. Unger, Thomas A. Fritz, Terry
                       Matsunaga, VaradaRajan Ramaswami, David Yellowhair, and
                       Guanli Wu.

                            Attachment B, Page 1 of 1

<PAGE>

Attachment C                                BMS-ImaRx Second Amendment Agreement

                                  ATTACHMENT C

UNGR-1600
DIV of BMS-0441 (formerly UNGR-1172)
U.S. Serial No. 09/813,484; Filed March 21, 2001
Novel Methods of Ultrasound Treatment Using Gas or Gaseous Precursor Filled
Compositions

UNGR-1632
DIV of BMS-0558 (formerly UNGR-1338)
U.S. Serial No. ____________________; Filed February 27, 2002
Novel Acoustically Active Drug Delivery Systems

UNGR-1633
DIV of BMS-0309 (formerly UNGR-0968); FF of BMS-0306 (formerly UNGR-0944)
China - Serial No. 02 1 05309.X; Filed February 22, 2002
Novel Targeted Compositions for Diagnostic and Therapeutic Use

UNGR-1634
DIV of BMS-0140 (formerly UNGR-0692); DIV of BMS-0139 (formerly UNGR-0348)
U.S. Serial No. ____________________; Filed March 26, 2002
Novel Therapeutic Delivery Systems.

                            Attachment C, Page 1 of 1<PAGE>

                                                                    Exhibit 10.9

                                LICENSE AGREEMENT

     THIS AGREEMENT is made by and between the Board of Trustees of the
University of Arkansas acting for and on behalf of the UNIVERSITY OF ARKANSAS
FOR MEDICAL SCIENCES, a public institution of higher education having principal
offices at 2404 North University Avenue, Little Rock, Arkansas 72207 United
States of America (hereinafter "UNIVERSITY"), and IMARX THERAPEUTICS, INC.
having a principal place of business at 1635 East 18th Street, Tucson, Arizona
85719 (hereinafter "LICENSEE").

                                 WITNESSETH

     WHEREAS, UNIVERSITY is the owner of certain PATENT RIGHTS (as later defined
herein) relating to certain technology invented by UNIVERSITY employees and
students of the UNIVERSITY and has the right to grant licenses under said PATENT
RIGHTS; and

     WHEREAS, UNIVERSITY desires to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant licenses there
under; and

     WHEREAS, LICENSEE desires to obtain a license under the PATENT RIGHTS upon
the terms and conditions hereinafter set forth.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the Parties hereto agree as follows:

                           ARTICLE 1 - EFFECTIVE DATE

     This Agreement shall be effective as of February 10, 2006 (hereinafter the
"EFFECTIVE DATE").

                             ARTICLE 2 - DEFINITIONS

     For the purposes of this Agreement, the following words and phrases shall
have the following meaning:

2.1 "PATENT RIGHTS" shall mean all of the following UNIVERSITY intellectual
property:

                               Page 1 of 18

<PAGE>

     (a) the United States and foreign patents and/or patent applications listed
     in Appendix A attached hereto, and corresponding foreign patents and/or
     foreign patent applications; and

     (b) United States patents issued from the applicatians listed in Appendix A
     and from applications for divisionals, continuations,
     continuations-in-part, reexaminations and reissues of the patents and/or
     applications listed in Appendix A and any divisionals, continuations,
     continuations-in-part, re-examinations and reissues issued from such
     applications and foreign patents issued from corresponding foreign: patent
     applications.

     (c) As used in this Agreement, the term "patent" means (i) unexpired
     letters patent (including inventor's certificates) including, without
     limitation, any substitution, extension (such as supplementary protection
     certificates), registration, confirmation, reissue, re-examination.
     renewal, or any like filing thereof, and (ii) pending applications for
     letters patent, including without limitation any continuation, division or
     continuation-in-part thereof and any provisional applications, and any
     foreign counterparts and all patents that issue there from.

2.2  "LICENSED PRODUCT" shall mean any product or part thereof which:

     (a) but for the license granted herein would infringe in whole or in part
     upon an issued, unexpired, valid claim or a pending claim contained in the
     PATENT RIGHTS in the country in which any such product or part thereof is
     made, used or sold; or

     (b) is manufactured by using a process or is employed to practice a process
     which, but for the license granted herein, would infringe in whole or in
     part upon an issued, unexpired valid claim or a pending claim contained in
     the PATENT RIGHTS in the country in which any LICENSED PROCESS is used or
     in which such product or part thereof is used or sold.

2.3 A "LICENSED PROCESS" shall mean any process, which is covered in whole or in
part by an issued, unexpired, valid claim, or a pending claim contained in the
PATENT RIGHTS.

2.4 "NET SALES" shall mean the gross revenues received by LICENSEE and its
agents, Affiliates, sublicensees and third parties for the sale of LICENSED
PRODUCTS less: returns, allowances, and discounts actually granted; packing,
insurance, freight out, taxes or excise duties imposed on the transaction (if
separately invoiced); wholesaler discounts and cash discounts. No

                                  Page 2 of 18

<PAGE>

deductions shall be made for commissions paid to individuals regularly employed
by LICENSEE and on its payroll, or for cost of collections. Notwithstanding the
foregoing, Net Sales shall not include any revenues with respect to: (i) any
LICENSED PROCESS or (ii) with respect to any product which is a LICENSED PRODUCT
solely with respect to claims 23 through 26 of US Patent No. 6,945,937, and any
corresponding claims in any other patent included in the PATENT RIGHTS, it being
the intent of the parties that the rights of LICENSEE hereunder with respect to
any LICENSED PROCESS and the foregoing claims shall be royalty free.

2.5 "FIRST COMMERCIAL SALE" shall mean the initial transfer by or behalf of
LICENSEE or its sublicensees of LICENSED PRODUCTS or the initial practice of a
LICENSED PROCESS by or on behalf of LICENSEE or its sublicensees in exchange for
cash or some equivalent to which value can be assigned for the purpose of
determining NET SALES.

2.6 "LICENSEE" is understood to include all of its Affiliates. An Affiliate of
LICENSEE shall mean any corporation or other business entity controlled by,
controlling or under common control with LICENSEE, For this purpose, "control"
means direct or indirect beneficial ownership of at least fifty percent (50%) of
the voting stock, or at least fifty percent (50%) interest in the income of such
corporation or other business.

2.7 "TERRITORY" shall mean the world.

2.8 "LICENSED FIELD" shall mean all applications.

                                ARTICLE 3 - GRANT

3.1 UNIVERSITY hereby grants to LICENSEE an exclusive right and license in the
TERRITORY for the LICENSED FIELD to practice under the PATENT RIGHTS and to
make, have made, use, offer for sell, sell and import LICENSED PRODUCTS and to
practice the LICENSED PROCESSES. Such licenses are hereby granted until the end
of the term of the PATENT RIGHTS unless this Agreement shall be sooner
terminated according to the terms hereof.

3.2 LICENSEE shall have the right to grant sublicenses consistent with this
Agreement provided that LICENSEE shall be responsible for the operations of its
sublicenses relevant to this Agreement as if such operations were carried out by
LICENSEE, including the payment of royalties whether or not paid to LICENSEE by
a sublicensee. LICENSEE further agrees to deliver to UNIVERSITY a true and
correct copy of each sublicense granted to LICENSEE, and

                                  Page 3 of 18
<PAGE>

any modification or termination thereof, within thirty (30) days after
execution, modification, or termination, which University shall maintain in
confidence per the terms of Article 17. Upon termination of this Agreement, any
and all existing sublicenses granted by LICENSEE shall survive and shall be
assigned to UNIVERSITY.

3.3 UNIVERSITY reserves the right to make and to use and to grant nonexclusive
licenses to non-profit entities to make and to use, for research purposes only
and not for any commercial purpose the technology and the subject matter
described and claimed in the PATENT RIGHTS.

                            ARTICLE 4 - DUE DILIGENCE

4.1 LICENSEE shall use commercially reasonable efforts to bring one or more
LICENSED PRODUCTS to market through an active and diligent program for
exploitation of the PATENT RIGHTS and to continue active, diligent marketing
efforts for one or more LICENSED PRODUCTS throughout the life of this Agreement.

4.2 In addition, LICENSEE shall use commercially reasonable efforts to adhere to
the following milestones:

     (a) LICENSEE shall deliver to UNIVERSITY on or before nine (9) months after
     the execution of this Agreement the preliminary business and FDA
     application and approval plans showing each phase of development of
     LICENSED PRODUCTS and shall provide similar reports to UNIVERSITY in
     accordance with Article 6.3 hereof.

     (b) LICENSEE shall develop an animal model / testing protocol of LICENSED
     PRODUCT on or before two years after execution of this Agreement.

     (c) LICENSEE shall proceed diligently toward obtaining appropriate United
     States regulatory approval for marketing LICENSED PRODUCTS and shall show
     appropriate and reasonable evidence toward same within five years of
     entering into Agreement.

4.3 LICENSEE's continued failure to perform in accordance with Articles 4.1 and
4.2 above for a period of 45 days after receiving from UNIVERSITY written notice
of default thereon, shall be grounds for UNIVERSITY, at sole option of
UNIVERSITY, to terminate this Agreement pursuant to Article 10 hereof or render
this license nonexclusive. In making this decision, UNIVERSITY shall take into
account the normal course of such activities conducted with sound

                                  Page 4 of 18

<PAGE>

and reasonable business practices and judgment and shall take into account the
reports provided hereunder by LICENSEE.

                  ARTICLE 5 - ROYALTIES AND OTHER CONSIDERATION

5.1 For the rights, privileges and license granted hereunder, LICENSEE shall pay
royalties and other compensation to UNIVERSITY in the manner hereinafter
provided to the end of the term of the PATENT RIGHTS or until this Agreement
shall be earlier terminated:

     (a) LICENSEE shall pay to UNIVERSITY on or before thirty (30) days after
     the EFFECTIVE DATE one half ($7,500) of a nonrefundable initial license
     fee of fifteen thousand dollars ($15,000) and the balance of $7,500 on or
     before the first anniversary of the EFFECTIVE DATE.

     (b) LICENSEE shall pay to UNIVERSITY twenty-five thousand dollars ($25,00O)
     within thirty (30) days after the FIRST COMMERCIAL SALE in the U.S.

     (c) LICENSEE shall pay to UNIVERSITY a minimum annual royalty in accordance
     with the following schedule:

          (i)  $5,000 per year commencing February 10, 2007, increasing to

          (ii) $7,000 per year on February 10, 2009, and each year thereafter.

     Such minimum royalty payments shall be offset against University Royalties
     due during the applicable year.

     (d) LICENSEE shall pay to UNIVERSITY the following running royalties
     ("UNIVERSITY Royalties"):

          (i)  4.0% of NET SALES of up to $1M;

          (ii) 3.0% of NET SALES greater than $1M, but less than $10M;

          (iii) 2.0% of NET SALES greater than $10M.

     Provided, however, that the total royalty payments paid by LICENSEE to
     UNIVERSITY shall not exceed $20M, and the license granted hereunder shall
     be royalty free after such amount has been paid.

                                  Page 5 of 18

<PAGE>

     (e) A one-time success payment of $250,000 in the first year that the
     aggregate Net Sales of LICENSED PRODUCTS exceeds $10M. This payment shall
     be made in addition to any royalties due.

     (f) Third Party Payments: LICENSEE shall pay UNIVERSITY fifteen percent
     (15%) of lump-sum non-royalty consideration actually received by LICENSEE
     from third party (ies) under a sublicensing agreement with LICENSEE;
     provided that, if LICENSEE has added substantial value or improvement to
     the LICENSED PRODUCTS, LICENSEE shall pay UNIVERSITY seven and one-half
     percent (7.5%) of such consideration. Substantial value or improvement is
     defined as FDA / regulatory approval for marketing LICENSED PRODUCTS. The
     foregoing payment obligation shall not apply with respect to consideration
     related to the provision of goods, services or equity ownership by LICENSEE
     to any sublicensee.

     (g) LICENSEE shall pay one hundred percent (100%) of the costs incurred in
     the preparation, filing, prosecution (including appeals, interferences, and
     other ex parte and inter partes proceedings) and maintenance of patent
     applications and patents by UNIVERSITY as of the EFFECTIVE DATE in
     accordance with the following schedule:

          (i)  $15,000 on the execution of this agreement and

          (ii) The balance of all patent costs incurred prior to the EFFECTIVE
               DATE twelve (12) months from the EFFECTIVE DATE of this
               agreement.

     (h) Should LICENSEE be required to pay royalties to a third party with
     respect to any patent rights of such third party ("Other Royalties") in
     order to make, have made, use, offer for sell, sell or import a particular
     LICENSED PRODUCT, LICENSEE shall be entitled to credit such Other Royalties
     against the UNIVERSITY royalties due hereunder, provided that the
     UNIVERSITY royalties shall not be reduced below fifty percent (50%) of
     those that would otherwise be due UNIVERSITY.

5.2 All amounts payable hereunder by LICENSEE shall be paid in full, without
deduction of taxes or other fees which may be imposed by any government and
which shall be paid by LICENSEE.

                                  Page 6 of 18

<PAGE>

5.3 No multiple or cumulative royalties shall be payable because any LICENSED
PRODUCT or LICENSED PROCESS, its manufacture, use, lease or sale are or shall be
covered by more than one PATENT RIGHTS patent application or PATENT RIGHTS
patent licensed under this Agreement.

5.4 All sales or use of LICENSED PRODUCTS by LICENSEE, excepting sales under
Article 8.1 to an Affiliate or another LICENSEE of UNIVERSITY, shall be subject
to royalty payments as provided.

                         ARTICLE 6 - RECORDS AND REPORTS

6.1 LICENSEE shall keep full, true and accurate books of account containing all
particulars that may be necessary for the purpose of showing the amounts payable
to UNIVERSITY hereunder. Said books of account shall be kept at LICENSEE's
principal place of business or the principal place of business of the
appropriate operating, subsidiary of LICENSEE to which this Agreement relates.
Said books and the supporting data shall be open, to the extent relevant to the
licenses granted hereunder, at all reasonable times for Five (5) years following
the end of the calendar year to which they pertain, to the inspection of
UNIVERSITY or his agents for the purpose of verifying LICENSEE's royalty
statement or compliance in other respects with this Agreement. Should such
inspection lead to the discovery of a greater than ten percent (10%) discrepancy
in reporting to UNIVERSITY's detriment, LICENSEE agrees to pay the full cost of
such inspection actually incurred by UNIVERSITY.

6.2 LICENSEE shall report to UNIVERSITY the date of first sale of a LICENSED
PRODUCT or LICENSED PROCESS in each country within thirty (30) days occurrence.

6.3 Prior to the FIRST COMMERCIAL SALE, LICENSEE shall make annual progress
reports to UNIVERSITY regarding both the milestones listed in Article 4 and
other measures of product development. These reports are due June 30 following
the EFFECTIVE DATE and prior to the FIRST COMMERCIAL SALE.

6.4 After the FIRST COMMERCIAL SALE of a LICENSED PRODUCT or LICENSED PROCESS,
LICENSEE, within sixty (60) days after March 31, June 30, September 30, and
December 31 of each year, shall deliver to UNIVERSITY true and accurate reports,
giving such particulars of the business conducted by LICENSEE and its
sublicensees with respect to the LICENSED PRODUCTS and LICENSED PROCESSES during
the preceding three-month

                                  Page 7 of 18

<PAGE>

period under this Agreement as shall be pertinent to a royalty accounting
hereunder. These shall include at least the following:

     (a)  quantity of LICENSED PRODUCTS manufactured and sold by LICENSEE;

     (b)  quantity of LICENSED PRODUCTS manufactured and sold by each
          sublicensee;

     (c)  total receipts for LICENSED PRODUCTS sold by LICENSEE;

     (d)  total receipts by LICENSEE for LICENSED PRODUCTS sold by each
          sublicensee;

     (e)  receipts for all LICENSED PROCESSES used or sold by LICENSEE

     (f)  receipts for all LICENSED PROCESSES used or sold by each sublicensee;

     (g)  deductions applicable as provided in Article 2.4;

     (h)  amounts due on additional payments from sublicensees under Article
          4.1(b);

     (i)  total royalties due; and

     (j)  names and addresses of each sublicensee of LICENSEE.

6.5 With each such report submitted, LICENSEE shall pay to UNIVERISITY the
royalties and other amounts then due and payable under this Agreement. If no
royalties or other amounts shall be due, LICENSEE shall so report.

                         ARTICLE 7 - PATENT PROSECUTION

LICENSEE shall apply for, seek prompt issuance of and maintain during the term
of this Agreement the PATENT RIGHTS in the United States and in the foreign
countries listed in Appendix A hereto. Appendix A may be amended by verbal
agreement of both Parties, such agreement to be confirmed in writing within ten
(10) days. The prosecution, filing and maintenance of all PATENT RIGHTS patents
and applications shall be the primary responsibility of LICENSEE, including
payment of all costs associated therewith; provided, however, UNIVERSITY shall
have reasonable opportunities to advise LICENSEE and shall cooperate with
LICENSEE in such prosecution, filing and maintenance.

                                  Page 8 of 18

<PAGE>

                ARTICLE 8 - OTHER TRANSFERS OF LICENSED PRODUCTS

8.1 It is anticipated that LICENSEE may supply LICENSED PRODUCTS or LICENSED
PROCESSES to another Licensee of UNIVERSITY for further processing and/or sale
by the Affiliate or sublicensee under PATENT RIGHTS. No royalty shall be payable
by LICENSEE with respect to such LICENSED PRODUCTS, so long as the Affiliate or
sublicensee shall be obligated to pay UNIVERSITY royalty under PATENT RIGHTS on
its use or sales thereof at a rate not less than that set forth in Article 5.1
(a) However, reports made by LICENSEE as provided in Article 6.3 shall list each
such transaction as a non-royalty-bearing sale and identify such Affiliate or
other LICENSEE.

8.2 If a royalty payment has been made to UNIVERSITY for a LICENSED PRODUCT used
by LICENSEE to make another LICENSED PRODUCT, that payment may be deducted by
LICENSEE from any royalty payment which would otherwise be owing with respect to
such resulting LICENSED PRODUCT, and is no event shall LICENSEE be required
under any circumstances to pay royalties in excess of the royalties payable
under this Agreement with respect to any LICENSED PRODUCT.

                            ARTICLE 9 - INFRINGEMENT

9.1 In the event of any action for infringement, or institution of any
proceedings challenging the validity of any of the patents under PATENT RIGHTS
in the LICENSED FIELD, LICENSEE shall have the right, but not the obligation, at
its own expense and in its own name, to prosecute actions or defend proceedings.
UNIVERSITY will assist LICENSEE in actions or proceedings, if so requested, and
will lend its name to actions or proceedings if required by LICENSEE or by law.
LICENSEE will assume all reasonable costs, which UNIVERSITY may incur in
affording assistance in actions or proceedings. If LICENSEE elects not to bring
any action for infringement, or defend any proceedings challenging the validity,
of any of the patents under PATENT RIGHTS as aforesaid, UNIVERSITY shall have
the right but not the obligation to bring action or defend proceedings in its
own name at its own expense. LICENSEE hereby agrees to lend its name to the
proceedings if a legally indispensable party and will render all reasonable
assistance on technical matters relating to the proceedings. In the event of a
recovery with respect to an action for infringement, UNIVERSITY and LICENSEE
shall first be reimbursed for costs of prosecuting or defending the action, and
any balance shall be paid to the Party defending or prosecuting the action.

                                  Page 9 of 18
<PAGE>

9.2 Upon payment by LICENSEE of costs incurred by either LICENSEE or UNIVERSITY
in any action for infringement, or defense of any proceedings challenging the
validity, of any patent under PATENT RIGHTS, LICENSEE may utilize a set-off for
all such litigation costs against royalty owed not to exceed fifty (50) percent
of royalties owed in a given year, with carry-over of set-off to future years of
this Agreement. Any recovery of damages by LICENSEE from each patent enforcement
or defense action shall be first applied to reimburse LICENSEE and UNIVERSITY
for such litigation costs not paid from royalties, then to reimburse UNIVERSITY
for royalties set-off and the balance, if any, to be shared equally.

                         ARTICLE 10 - PRODUCT LIABILITY

10.1 LICENSEE shall at all times during the term of this Agreement and
thereafter, indemnify, defend and hold UNIVERSITY, its trustees, directors,
officers, employees and affiliates, harmless against all claims, proceedings,
demands and liabilities of any kind whatsoever, including legal expenses and
reasonable attorneys' fees, arising out of the death of or injury to any person
or persons or out of any damage to property, or resulting from the production,
manufacture, sale, use, consumption or advertisement of the LICENSED PRODUCTS
and/or LICENSED PROCESSES by or on behalf of LICENSEE or arising from any
obligation of LICENSEE hereunder, excepting only claims that the PATENT RIGHTS
infringe third party intellectual property and any claims arising out of
negligence or willful misconduct of UNIVERSITY, its trustees, directors,
officers, employees and affiliates.

10.2 Prior to the FIRST COMMERCIAL SALE, LICENSEE shall obtain and carry in full
force and effect commercial, general liability insurance, which shall protect
LICENSEE and UNIVERSITY with respect to events, covered by Article 10.1 above.
Such insurance shall be written by a reputable insurance company authorized to
do business in the State of Arkansas, shall list UNIVERSITY as an additional
named insured there under, shall be endorsed to include product liability
coverage and shall require thirty (30) days written notice to be given to
UNIVERSITY prior to any cancellation or material change thereof. The limits of
such insurance shall not be less than one million dollars ($1,000,000) per
occurrence with an aggregate of three million dollars ($3,000,000) for personal
injury or death, and one million dollars ($1,000,000) per occurrence with an
aggregate of three million dollars ($3,000,000) for property damage. LICENSEE
shall provide UNIVERSITY with Certificates of Insurance evidencing the same.

10.3 UNIVERSITY hereby represents and warrants to LICENSEE: (i) that UNIVERSITY
is the owner of the PATENT RIGHTS, and (ii) that UNIVERSITY has the power and
authority to enter into the is Agreement and grant the rights granted hereunder,
and (iii) that to the actual

                                  Page 10 of 18

<PAGE>

knowledge of UNIVERSITY the exercise by LICENSEE of the rights granted pursuant
to this Agreement will not infringe upon the intellectual property rights of any
third party. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
UNIVERSITY, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND. EITHER EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY. FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE
ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS
AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY
UNIVERSITY THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL
NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL UNIVERSITY.
ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR
INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR
INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER UNIVERSITY SHALL BE
ADVISED. SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
POSSIBILITY.

                          ARTICLE 11 - EXPORT CONTROLS

     It is understood that UNIVERSITY is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended, and the Export Administration Act of 1979), and that its
obligations hereunder are contingent on the compliance with applicable United
States export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United States
Government and/or written assurances by LICENSEE that LICENSEE shall not export
data or commodities to certain foreign countries without prior approval of such
agency. UNIVERSITY neither represents that a license shall not be required nor
that, if required, it shall be issued.

                          ARTICLE 12 - NON-USE OF NAMES

     LICENSEE shall not use the name of UNIVERSITY, nor any adaptation thereof,
in any advertising, promotional or sales literature without prior written
consent of UNIVERSITY, except that LICENSEE may state that it is licensed by
UNIVERSITY under one or more of the patents and/or applications comprising the
PATENT RIGHTS.

                                  Page 11 of 18

<PAGE>

                            ARTICLE 13 - ASSIGNMENT

     This Agreement shall not be assigned except with the advance written
consent of UNIVERSITY, provided that no such consent shall be required with
respect to any assignment in connection with any sale, merger or other
transaction involving the transfer of substantially all of the assets of
LICENSEE'S business to which this Agreement relates; provided that such assignee
agrees in writing to be bound by all the terms and conditions of this Agreement.
Failure of assignee to so agree shall be grounds to terminate this Agreement by
UNIVERSITY pursuant to Section 15.2.

                         ARTICLE 14 - DISPUTE RESOLUTION

14.1 Except for the right of either Party to apply to a court of competent
jurisdiction for a temporary restraining order, a preliminary injunction, or
other equitable relief to preserve the status quo or prevent irreparable harm,
any and all claims, disputes or controversies arising under, out of, or in
connection with the Agreement which the Parties shall be unable to resolve
within sixty (60) days shall be mediated in good faith. The Party raising such
dispute shall promptly advise the other Party of such claim, dispute, or
controversy in writing, which describes in reasonable detail the nature of such
dispute. By not later than fifteen (15) business days after recipient has
received such notice of dispute, each Party shall have selected for itself a
representative who shall have the authority to bind such Party and shall
additionally have advised the other Party in writing of the name and title of
such representative. By not later than thirty (30) business days after such
notice of dispute, the Party against whom the dispute shall be raised shall
select a mediation firm and such representatives shall schedule a date with such
firm for a mediation hearing. The Parties shall enter into good faith mediation
and shall share the costs equally. If the representatives of the Parties have
not been able to resolve the dispute within thirty (30) business days after such
mediation hearing, the Parties shall have the right to pursue any other remedies
legally available to resolve such dispute in any court of competent
jurisdiction.

14.2 Notwithstanding the foregoing, nothing in this Article shall be construed
to waive any rights or timely performance of any obligations existing under this
Agreement or the sovereign immunity of the UNIVERSITY or the State of Arkansas.

                                  Page 12 of 18
<PAGE>

                        ARTICLE 15 - TERM AND TERMINATION

15.1 The term of this Agreement shall extend from the EFFECTIVE DATE until
expiration of the last to expire patents under PATENT RIGHTS.

15.2 Upon any breach of, or default under, this License Agreement by LICENSEE,
UNIVERSITY may terminate this License Agreement by ninety (90) days written
notice to LICENSEE. Said notice shall become effective at the end of such period
unless during said period LICENSEE shall cure such defect or default.

15.3 LICENSES shall have the right to terminate this Agreement any time upon
ninety (90) days written notice to UNIVERSITY.

15.4 Upon termination of this Agreement for any cause, nothing herein shall be
construed to release either Party of any obligation matured prior to the
effective date of such termination. LICENSEE may, after the effective date of
such termination, sell all LICENSED PRODUCTS and parts thereof that it may have
on hand at the date of termination, provided that it pays earned royalties
thereon as provided in this Agreement.

             ARTICLE 16 - PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

16.1 Any payment, notice or other communication pursuant to this Agreement shall
be sufficiently made or given on the date of mailing if sent to such Party by
certified first class mail, postage prepaid, addressed to it at its address
below or as it shall designate by written notice given to the other Party:

     LICENSEE:

     ImaRx Therapeutics, Inc.
     1635 East 18th Street
     Tucson, Arizona 85719
     Attention: Greg Cobb, CFO

     UNIVERSITY:

     University of Arkansas for Medical Sciences
     4301 West Markham Street #831
     Little Rock, Arkansas 72205
     Attention: Charles Cook

                                  Page 13 of 18

<PAGE>

     With copy to:

     Williams & Anderson PLP
     Twenty-Second Floor
     111 Center Street
     Little Rock, Arkansas 72201
     Attention: Harold J. Evans

                          ARTICLE 17 - CONFIDENTIALITY

17.1 Each party agrees to protect the Confidential Information of the other
party with at least the same degree of care with which it protects its own
Confidential Information (but in no event less than reasonable care), and not to
use any such information other that in connection with its rights and
obligations under this Agreement. Confidential Information with respect to a
Party, includes all information of any kind whatsoever (and all tangible and
intangible embodiments thereof of any kind whatsoever) which is owned or
controlled by such Party, is disclosed by such Party to the other Party pursuant
to this Agreement, and (if disclosed in writing or other tangible medium) is
marked or identified as confidential at the time of disclosure to the receiving
Party or (if otherwise disclosed) is identified as confidential at the time of
disclosure to the receiving Party. Notwithstanding the foregoing, Confidential
Information of a Party shall not include information which the receiving Party
can establish by written documentation (a) to have been publicly known prior to
disclosure of such information by the disclosing Party to the receiving Party,
(b) to have become publicly known, without fault on the part of the receiving
Party, subsequent to disclosure of such information by the disclosing Party to
the receiving Party, (c) to have been received by the receiving Party at any
time from a source, other than the disclosing Party, rightfully having
possession of and the right to disclose such information free of confidentiality
obligations, (d) to have been otherwise known by the receiving Party free of
confidentiality obligations prior to disclosure of such information by the
disclosing Party to the receiving Party, or (e) to have been independently
developed by employees or agents of the receiving Party without access to or use
of such information disclosed by the disclosing Party to the receiving Party.
The Parties acknowledge that the foregoing exceptions shall be narrowly
construed and that the obligations imposed upon each Party shall be relieved
solely with respect to such Confidential Information of the disclosing Party
which falls within the above exceptions and not with respect to related
portions, other combinations, or characteristics of the Confidential Information
of the disclosing Party including, without limitation, advantages, operability,
specific purposes, uses and the like.

                                  Page 14 of 18

<PAGE>

                              ARTICLE 18 - GENERAL

18.1 Legal Compliance. LICENSEE shall comply with all applicable federal, state
and local laws and regulations in connection with its activities pursuant to
this Agreement.

18.2 Patent Marking. LICENSEE agrees to mark the LICENSED PRODUCTS sold in the
United States with all applicable United States patent numbers. All LICENSED
PRODUCTS shipped to or sold in other countries shall be marked in such a manner
as to conform to the patent laws and practice of the country of manufacture or
sale.

18.3 Exports. It is understood that UNIVERSITY is subject to United States laws
and regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended and the Export Administration Act of 1979), and that its
obligations hereunder are contingent on compliance with applicable United States
export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United States
Government and/or written assurances by LICENSEE that LICENSEE shall not export
data or commodities to certain foreign countries without prior approval of such
agency. UNIVERSITY neither represents that a license shall not be required nor
that, if required, it shall be issued.

18.4 Waiver. Neither Party may waive or release any of its rights or interests
in this Agreement except in writing. Failure to assert any right arising from
this Agreement shall not be deemed or construed to be a waiver of such right.

18.5 Integration. This Agreement constitutes the entire agreement between the
Parties relating to the subject matter thereof, and all prior negotiations,
representations, agreements, and understandings are merged into, extinguished
by, and completely expressed by it.

18.6 Effect of Agreement. This Agreement is binding upon the Parties hereto, and
shall inure to the benefit of the Parties, and their respective agents,
attorneys, insurers, employees, representatives, officers, directors, partners,
principals, divisions, indemnitors, indemnitees, parent companies, grandparent
companies, subsidiaries, affiliates, associates, consultants, assigns, heirs,
predecessors, and successors in interest, successor trusts, trustees,
shareholders and any trustee in bankruptcy or debtor in possession.

18.7 Construction and Interpretation. This Agreement and its effect are subject
to and shall be construed and enforced in accordance with the laws of the State
of Arkansas without regard to its

                                  Page 15 of 18
<PAGE>

choice of law principles. The drafting and negotiation of this Agreement have
been participated in by counsel for each of the Parties, and any rule of
construction to the effect that any ambiguity is to be resolved against the
drafting Party shall not be applied to the interpretation of this Agreement.

18.8 Severability. The provisions of this Agreement are severable, and in the
event that any provisions of this Agreement shall be determined to be invalid or
unenforceable under any controlling body of the law, such invalidity or
unenforceability shall not in any way affect the validity or enforceability of
the remaining provisions hereof.

18.9 Representation by Counsel. The Parties hereby acknowledge that counsel has
represented each such Party and that this Agreement has been executed with the
consent and advice of counsel.

18.10 Execution and Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original. All counterparts
together shall constitute one and the same original.

18.11 Authority. Each Party represents and warrants for itself that the
individual executing this Agreement on its behalf is authorized to do so and to
bind the Party on whose behalf he is signing to the terms, obligations and
conditions set forth herein.

18.12 Modification or Amendment. This Agreement may not be modified or amended
except in writing signed by all Parties hereto.

18.13 Further Assurance and Documents. The Parties, and each of them, agree to
execute any and all additional documents and to do all things reasonably
necessary to carry out and implement the provisions of this Agreement.

                <Remainder of this page intentionally left blank>

                                  Page 16 of 18

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their duly authorized representatives.

THE BOARD OF TRUSTEES OF THE            IMARX THERAPEUTICS, INC.
UNIVERSITY OF ARKANSAS

/s/ Ann Kemp                            /s/ Greg Cobb
-------------------------------------   ----------------------------------------
By: Ann Kemp                            By: Greg Cobb
Title: Vice President for               Title: CEO
       Finance and Administration

Date: 2/14/06                           Date: 2/8/06

                                  Page 17 of 18

<PAGE>

                                   APPENDIX A

US, Patent #6,945,937, issued 09/20/05
Inventor: Dr. William Culp, et al.
for "Ultrasound Apparatus and Method for Microbubble Augmented Clot Lysis"

PCT/US2004/028934 filed 09/03/04

Patent Costs $27,815 as of 02/02/06

                                  Page 18 of 18
<PAGE>

                            ImaRx Therapeutics, Inc.
                              1635 East 18th Street
                              Tucson, Arizona 85719

                         Exclusive License Terms Summary

Licensee: ImaRx Therapeutics, Inc. (less than 50 employees)

Effective Date: February 10, 2006

IP: UAMS I03-33 (Culp) U.S. Patent # 6,945,937,
"Ultrasound Apparatus and Method for Microbubble Augmented Clot Lysis"

Co-inventor James D. Wilson, (UALR - 50:50)

National patent filings in-work: Japan, Canada, Europe and Australia.

Licensee Pays 100% of all Patent Costs and takes over all patent prosecution

February 20, 2006, on or before:
     $15,000 - approx. one half patent cost reimbursement (1 of 2)

March 10, 2006
     $7,500 one half initial license fee of fifteen thousand dollars ($15,000)

November 10, 2006
     Preliminary business and FDA application and approval plans

February l0, 2007
     $7,500 balance of license fee
     ~$15,000 balance of all patent costs incurred prior to February 10, 2006
     $5,000 Min Annual royalty, increasing to $7,000 per year on February 10,
     2009

February 10, 2008
     Develop an animal model / testing protocol

February 10, 2009
     $7,000 Min Annual royalty increase and each year thereafter

February 10, 2011
     United States regulatory approval

First Commercial Sale + 30days
     $25,000

Royalties
     4.0% of NET SALES of up to $1M;
     3.0% of NET SALES greater than $1M, but less than $10M;
     2.0% of NET SALES greater than $10M
     Total royalty payments paid capped at $20M

<PAGE>

Success payment - one time payment of $250,000 in the first year that the
     aggregate Net Sales exceeds $10M. This payment shall be made in addition to
     any royalties due.

Third Party Payments:
     15% of consideration received by LICENSEE from third parties under a
     sublicensing agreement

     7.5% after FDA/regulatory approval.

Reports:

     June 30, 2006 and prior to the FIRST COMMERCIAL SALE, annual progress
     reports

     After the first commercial sale, within sixty (60) days after March 31,
     June 30, September 30, and December 31 of each year

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]